Section 3 of 6
Product information and disease description
391 evidence topics · 218 sources
Product description
Phase of product development
Regulatory status: Under review; NDA submitted November 2026
Launch: Anticipated in the first half of 2027
FDA review timeline under the Commissioner's National Priority Voucher
Breakthrough Therapy designation, October 2018
Rolling review and Commissioner's National Priority Voucher, April 2026
UK Innovation Passport under the Innovative Licensing and Access Pathway
Federal rescheduling by the DEA required before marketing
Executive Order 14401 on timely rescheduling and priority vouchers for psychedelic drugs
State rescheduling: over 93% of the U.S. population in states intending to reschedule within 30 days of federal action
Pipeline: PIVOT, a Department of Veterans Affairs trial of COMP360 in veterans with TRD
Pipeline: COMP 104, a phase 2 trial in recurrent major depressive disorder
Pipeline: post-traumatic stress disorder, phase 2b/3 Redefine trial (COMP202)
Pipeline: anorexia nervosa, phase 2 trial reported August 2025
NDA submission within two weeks, November 2026, superseded in November 2026
NDA submission completion in the fourth quarter of 2026, March to September 2026, superseded in November 2026
State rescheduling: approximately 90% of the U.S. patient population, August 2026, superseded in November 2026
Launch readiness by the end of 2026, March and May 2026, superseded in August 2026
Acceleration of commercialization readiness by 9 to 12 months, November 2025, superseded in March 2026
Phase 3 data timing: COMP005 in the second quarter of 2025 and COMP006 in the second half of 2026, October 2024, superseded in November 2025
Phase 3 data timing: COMP005 in the fourth quarter of 2024 and COMP006 in mid-2025, August 2024, superseded in October 2024
Product information
Generic, brand name and therapeutic class of product
Manufacturer: COMPASS Pathways
Formulation: polymorphic crystalline synthetic psilocybin
Therapeutic class: classic psychedelic, potentially first in class
Dosage forms and strengths
Doses studied in the phase 2b trial: 25 mg, 10 mg, and 1 mg
“we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose evaluated for retreatment in phase 3: 25 mg
Capsule strength in investigator studies: 5 mg capsules given as five capsules
“The study drug was administered simultaneously to up to six participants as a single 5-capsule oral dose (psilocybin 10 mg: 2 × 5 mg psilocybin capsules plus 3 × placebo capsules; psilocybin 25 mg: 5 × 5 mg psilocybin capsules; placebo: 5 × placebo capsules).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
United States controlled substance schedule: Schedule I
United Kingdom controlled drug classification: Class A and Schedule 1
Indication
Indication sought in the NDA: treatment-resistant depression
Company definition of TRD as a subset of major depressive disorder
Pharmacology
Mechanism of action
Psilocybin as a prodrug of psilocin, a partial agonist at serotonin receptors
“The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Downstream signaling and neuroplasticity
Absence of serotonin release or reuptake inhibition
“Psilocybin and psilocin lack clinically significant inhibitor activity at monoamine reuptake pumps, such as SERT or VMAT-2, thus do not result in substantially increased intrasynaptic serotonin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to minimal intrasynaptic serotonin release, psilocybin’s mechanism of action is unlikely, even in high doses, to result in serotonin toxicity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Brain 5-HT2A receptor occupancy and plasma psilocin
“Psilocybin intake resulted in dose-related 5-HT2AR occupancies up to 72%; plasma psilocin levels and 5-HT2AR occupancy conformed to a single-site binding model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjective intensity was correlated with both 5-HT2AR occupancy and psilocin levels as well as questionnaire scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Occmax [95% CI] determined from this model was 76.6 [67.3; 88.0]%, EC50 [95% CI] was 1.95 [1.17; 3.15] μg/L, and R2 was 0.92” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Important for clinical studies, psilocin time-concentration curves varied but psilocin levels were closely associated with psychedelic experience.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time course and dose dependence of subjective effects
Onset and resolution of acute effects with COMP360 in healthy participants
“In total, 511 TEAEs were reported, with a median duration of 1.0 day; 67% of all TEAEs started and resolved on the day of administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“255 started on the administration day, 235 (92%) of which were resolved that day” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular effects: blood pressure, heart rate, and QTc interval with COMP360
Cognitive function and emotional processing after a single dose of COMP360
“There were no clinically relevant between-group differences in CANTAB global composite score, CANTAB cognitive domain scores, or emotional processing scale scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results indicate that 10 mg and 25 mg doses of psilocybin were generally well tolerated when given to up to six participants simultaneously and did not have any detrimental short- or long-term effects on cognitive functioning or emotional processing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical and in vitro pharmacology of psilocin metabolites
“Neither 4-HIAA nor 4-HTP showed relevant interactions at assessed 5-HT receptors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The major metabolite 4-HIAA and 4-HTP were inactive at human 5-HT receptors but the activity of oxidized psilocin metabolites and norpsilocin remain to be assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Absorption, dephosphorylation to psilocin, and distribution
“Psilocybin is rapidly dephosphorylated to psilocin, which is absorbed with Tmax values ranging from 1.8 to 4 h following oral administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One study reported psilocin bioavailability at 52.7 ± 20%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The volume of distribution was extensive, ranging from 277 ± 92 L to 1016 L, suggesting significant tissue distribution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Elimination half-life varied across studies, ranging from 1.5 to 4 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fixed oral doses of 15, 25, and 30 mg: maximal concentration, time to peak, and half-life
Weight-based escalating doses and equivalence of the 25 mg fixed dose
“No psilocybin was found in plasma or urine, and renal clearance of intact psilocin accounted for less than 2% of the total clearance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The pharmacokinetics of psilocin were linear within the twofold range of doses, and the elimination half-life of psilocin was 3 h (standard deviation 1.1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“An extended elimination phase in some subjects suggests hydrolysis of the psilocin glucuronide metabolite.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Simulation of fixed doses using the pharmacokinetic parameters suggest that an oral dose of 25 mg should approximate the drug exposure of a 0.3 mg/kg oral dose of psilocybin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Metabolism: glucuronidation by UGT1A10 and UGT1A9
“UGT1A10 exhibited the highest psilocin glucuronidation activity, whereas the activities of UGTs 1A9, 1A8, 1A7, and 1A6 were significantly lower.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“suggest that whereas psilocin may be subjected to extensive glucuronidation by UGT1A10 in the small intestine, UGT1A9 is likely the main contributor to its glucuronidation once it has been absorbed into the circulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolism: monoamine oxidase A, CYP2D6, and CYP3A4
“MAO-A transformed psilocin into minimal amounts of 4-HIAA and 4-HTP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the CYP2D6 genotype did not influence psilocin plasma concentrations in the investigated study population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, MAO-A, CYP2D6, and CYP3A4 are involved in psilocin’s metabolism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CYP2D6 and CYP3A4 seem to be involved to a minor extent in psilocin’s metabolism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elimination in urine as psilocin glucuronide, 4-HIAA, and unconjugated psilocin
COMP360 single-dose pharmacokinetic and food-effect study in healthy volunteers
COMP360 pharmacokinetics in recurrent major depressive disorder
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Participants aged 65 years and older in the phase 3 trials
| Trial and arm | Age, years, minimum and maximum | Age 65 years or older, n (%) |
|---|---|---|
| COMP005, COMP360 25 mg (N=171) | “19, 77” | “15 (8.8)” |
| COMP005, placebo (N=87) | “22, 72” | “11 (12.6)” |
| COMP006, COMP360 25 mg (N=296) | “18, 79” | “29 (9.8)” |
| COMP006, COMP360 10 mg (N=142) | “19, 73” | “9 (6.3)” |
| COMP006, COMP360 1 mg (N=143) | “20, 75” | “13 (9.1)” |
Hepatic and renal impairment: regulatory expectation for dedicated studies
Hepatic function, cardiovascular disease, and seizure disorders as exclusions in the COMP360 pharmacokinetic study
Pregnancy and breastfeeding
Psychiatric and treatment-history exclusions in the phase 3 trials
Regulatory expectation for representative trial populations
Drug/Drug, drug/disease interactions
Effects of other drugs on Psilocybin
Regulatory summary of interactions with antidepressants and lithium
SSRIs and SNRIs: attenuation of psilocybin effects in survey reports
“In reports (n = 611) of taking mushrooms with an antidepressant, probabilities [95% CI] of weaker than expected drug effects were 0.47 [0.41-0.54] (selective serotonergic reuptake inhibitors, SSRIs), 0.55 [0.44-0.67] (serotonin norepinephrine reuptake inhibitors, SNRIs) and 0.29 [0.2-0.39] (bupropion).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SSRI/SNRIs appear to weaken psilocybin drug effects relative to a non-serotonergic antidepressant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This dampening effect may last as long as 3 months following antidepressant discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Escitalopram pretreatment before psilocybin 25 mg in healthy participants
“Pretreatment consisted of 10 mg escitalopram daily for 7 days, followed by 20 mg daily for 7 days, including the day of psilocybin administration, or 14 days of placebo pretreatment before psilocybin administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Escitalopram pretreatment had no relevant effect on positive mood effects of psilocybin but significantly reduced bad drug effects, anxiety, adverse cardiovascular effects, and other adverse effects of psilocybin compared with placebo pretreatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Escitalopram did not alter the pharmacokinetics of psilocin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further studies are needed with a longer antidepressant pretreatment time and patients with psychiatric disorders to further define interactions between antidepressants and psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ongoing SSRI treatment with COMP360 25 mg in treatment-resistant depression
“There were meaningful improvements in depression severity from Baseline to Week 3, indicating that ongoing SSRI treatment did not inhibit the therapeutic potential of psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Taken together, these findings suggest that the pharmacological interactions necessary for psilocybin to take effect are not meaningfully compromised by SSRIs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recent antidepressant discontinuation before COMP360 in the phase 2b trial
“Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chronic antidepressant exposure and 5-HT2A receptors in preclinical studies
“More convincingly, chronic administration of antidepressant drugs, including a selective serotonin reuptake inhibitor (SSRI), reduced the head-twitch response, a stereotypic behavior exhibited by rodents in response to 5-HT2A agonizts and also downregulated 5-HT2A receptors, which are considered essential for the subjective psychedelic effects of psilocybin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lithium and seizures
“They found that 2 of the 6 reports of lithium plus psilocybin resulted in seizures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the 10 reports of lamotrigine plus psilocybin resulted in seizures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monoamine oxidase inhibitors
“Inhibition of psilocin inactivation by MAO could potentially augment the metabolic pathway catalyzed by CYP2D6, thereby altering the pharmacodynamics of psilocybin therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, glucuronidation of psilocin would likely continue to be the predominant metabolic pathway, rendering MAO inhibition potentially less important.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
UGT1A9 and UGT1A10 inhibitors and estradiol
“Diclofenac and probenecid are examples of UGT1A9/10 inhibitors that may hypothetically alter psilocybin metabolism if co-ingested; however, there is no evidence to confirm this hypothesis beyond shared metabolism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There are few pharmacologic agents that influence UGT1A9 and UGT1A10” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This suggests that hormone replacement therapy, oral contraceptives, and cyclical hormonal changes may affect the metabolism of psilocybin, highlighting the need for more inclusive research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antipsychotics and 5-HT2A receptor antagonists
“Haloperidol pretreatment reduced psilocybin effects on the Oceanic boundlessness, measures of derealisation and depersonalisation phenomena but increased anxiety without any effects on visual hallucinations or delayed response tasks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Risperidone pretreatment attenuated the effects of psilocybin in a dose-dependent manner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ketanserin pretreatment blocked psilocybin effects in a dose-dependent manner on the delayed response task and Altered State of Consciousness Rating scale.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Except for a few case reports, no serious adverse drug events were described in the included studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effects of Psilocybin on other drugs
In vitro inhibition of cytochrome P450 isoforms by psilocin
Dosing and administration
Dosage
Single 25 mg dose in COMP005 and two fixed doses in COMP006
Dose response in the phase 2b trial
Retreatment in Parts B and C of the phase 3 trials
Dosing the company intends to seek in labeling
Capsule strength and count in the phase 1 study
“The study drug was administered simultaneously to up to six participants as a single 5-capsule oral dose (psilocybin 10 mg: 2 × 5 mg psilocybin capsules plus 3 × placebo capsules; psilocybin 25 mg: 5 × 5 mg psilocybin capsules; placebo: 5 × placebo capsules).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory expectations for evaluating repeat dosing
Administration
Preparation, administration session of approximately six to eight hours, and post-administration follow-up
Session setting and discharge
Preparatory and follow-up sessions in the phase 2b trial
Compass Psychological Support Model and therapist training
“The authors describe the Compass Psychological Support Model (CPSM), currently used to support participants with treatment-resistant depression in Compass-sponsored clinical trials of investigational COMP360 psilocybin treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The authors also outline the therapist training, mentoring, and fidelity assessment programs they have developed to ensure the quality and consistency of the CPSM delivery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Support provided during administration sessions
Monitoring by healthcare professionals
Simultaneous dosing of several participants
Fasting and water intake in the COMP360 pharmacokinetic study
Serotonergic antidepressant taper before dosing in the phase 2b trial
Access and distribution
Risk Evaluation and Mitigation Strategy expected, modeled on the Spravato REMS
Prescriber and provider training
Administration at a certified treatment center with session monitoring
Monitoring staffing: one primary monitor and closed-circuit television, two healthcare providers in total
Treatment-center network: more than 8,500 interventional psychiatry centers
Distribution channels: specialty pharmacy and buy-and-bill, reimbursed through the pharmacy benefit
Monitoring billed through CPT Category III codes for psychedelic drug monitoring
“CPTIII codes specifically for psychedelics” (opens the source at this quote in a new tab)
“billed by the hour through medical benefit” (opens the source at this quote in a new tab)
Payer engagement, reimbursement assistance, and patient support
Current reimbursement status of psilocybin as a Schedule I substance
Federal and state rescheduling as a precondition of prescribing and distribution
Co-prescribed/Concomitant therapies
Discontinuation of prohibited medications before dosing in the phase 3 trials
Antidepressant discontinuation during screening in the phase 2b trial
“Data from 233 participants with treatment-resistant depression (TRD) who received 25 mg, 10 mg, or 1 mg of investigational drug COMP360 psilocybin (a proprietary, pharmaceutical-grade synthetic psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.), administered with psychological support, were compared for groups of participants who either discontinued one or more antidepressant drugs during screening or entered the trial antidepressant drug free.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Suicidality was comparable between groups at Baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Withdrawal of antidepressant, antipsychotic, and mood-stabilizing drugs in the PsiDeR trial
Adjunctive SSRI: COMP360 25 mg with an ongoing SSRI
“Participants were taking a locally approved therapeutic dose of a single SSRI with at least 75% adherence for a minimum of six weeks prior to taking part and were asked to continue this treatment for the duration of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants continued their SSRI medication throughout the follow-up period and to the end of the study (Week 3); two participants on escitalopram increased their dose (10–20 mg) during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twelve (63.2%) participants had a TEAE, most of which were mild and resolved on the day of onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no serious TEAEs or indication of increased suicidal ideation or behavior.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Larger, comparator-controlled trials are necessary to understand if this paradigm can optimize treatment-outcome where antidepressant drug withdrawal would be problematic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive antidepressant permitted in the company's PTSD trial
Concomitant psychotherapy
Rescue medication during an administration session
“An AE of substance induced psychotic disorder was reported for a participant who became behaviourally disinhibited during the acute drug experience.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a medical assessment, 2.5 mg oromucosal midazolam was administered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The participant recovered with no sequelae and was discharged 11 h after receiving the study intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of Psilocybin on quality measures
HEDIS Antidepressant Medication Management (AMM): definition and rationale
HEDIS Antidepressant Medication Management: retirement for measurement year 2025
HEDIS Depression Screening and Follow-Up for Adolescents and Adults (DSF-E): definition
HEDIS Depression Remission or Response for Adolescents and Adults (DRR-E): definition and use of the PHQ-9
Electronic clinical quality measure CMS159v14, Depression Remission at Twelve Months: definition and rationale
Electronic clinical quality measure CMS2v15, Screening for Depression and Follow-Up Plan: definition
Medicaid Adult Core Set: mandatory depression screening measure for 2027
Product comparison
Approved pharmacotherapies for TRD in the United States
Comparators in the ICER assessment of synthetic psilocybin
Dosing frequency compared with esketamine: company statements
Session monitoring time compared with esketamine: six hours and two hours
Onset and durability: company statements on differentiation
TRD indication compared with psychedelics developed for major depressive disorder
Usona Institute psilocybin in major depressive disorder
Helus Pharma deuterated psilocin analog as adjunctive treatment of major depressive disorder
Other late-stage psychedelic candidates in depression and TRD
Polymorph patent coverage relative to other oral psilocybin products
REMS differences expected between psilocybin and MDMA
Place of product in therapy
Disease description
Definition and etiology
Definition: FDA draft guidance on trials in treatment-resistant depression
Definition: EMA guideline on treatment resistance
Definition: regulatory definition and absence of a validated consensus definition
“A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision‐making and health outcomes does not currently exist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have adopted the most used definition of TRD (i.e., inadequate response to a minimum of two antidepressants despite adequacy of the treatment trial and adherence to treatment).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The EMA definition, contrary to the FDA one, explicitly states that the failed antidepressants can be from the same or different mechanistic classes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limitations of the FDA and EMA definitions are that they do not explicitly operationalize non‐response, and do not consider psychotherapeutic interventions, regarded as first‐line treatments for mild or moderate depression by most guidelines” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition: review of expert and trial definitions for AHRQ and CMS
“We found that no consensus definition existed for TRD. The most common TRD definition for major depressive disorder required a minimum of two prior treatment failures and confirmation of prior adequate dose and duration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our systematic review found that only 17% of intervention studies enrolled samples meeting the most frequently specified criteria for TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Definition: systematic review of definitions in research and clinical practice
“In total, 155 definitions for TRD were identified in the published literature, and 48.4% of all definitions specified requirement of at least 2 treatment failures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key informant interviews indicated the concept of TRD is rarely employed in clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition: Delphi consensus criteria for regulatory clinical trials
“Based on a number of guidelines and other expert documents [22–25], in this report we adopt the definition of TRD as indicating individuals who show a reduction of less than 25% in MDD severity to at least two antidepressants, and of PRD as indicating individuals who show a reduction of between 25% and <50% in MDD severity to at least one antidepressant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend (with moderate consensus, 74%) that the criteria of ‘adequate dose and duration’ is the minimal effective dosage, that is, the minimal approved dosage, administered for at least four weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition: CANMAT 2023 guideline
Definition: population in the ICER assessment of psilocybin
Related concept: difficult-to-treat depression
“The group proposed that DTD be defined as "depression that continues to cause significant burden despite usual treatment efforts".” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While DTD would seem to have clinical utility, its specificity and objectivity may be insufficient to define clinical populations for regulatory trial purposes” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: heterogeneous causal mechanisms
“Treatment Resistant Depression (TRD) represents a heterogeneous state with likely multiple causal mechanisms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The extent to which individuals with TRD versus treatment-responsive MDD differ in etiology or pathophysiology remains mostly obscure” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both childhood adversity and stress in adulthood predict increased TRD following antidepressant treatments” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: familial aggregation in a nationwide Taiwanese cohort
“TRD was defined as having experienced at least 3 distinct antidepressant treatments in the current episode, each with adequate dose and duration, based on the prescribing records.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First-degree relatives of individuals with TRD had lower incomes, more physical comorbidities, higher suicide mortality, and increased risk of developing TRD (aRR, 9.16; 95% CI, 7.21-11.63) and higher risk of other psychiatric disorders than matched control individuals, including schizophrenia (aRR, 2.36; 95% CI, 2.10-2.65), bipolar disorder (aRR, 3.74; 95% CI, 3.39-4.13), major depressive disorder (aRR, 3.65; 95% CI, 3.44-3.87), attention-deficit/hyperactivity disorders (aRR, 2.38; 95% CI, 2.20-2.58), autism spectrum disorder (aRR, 2.26; 95% CI, 1.86-2.74), anxiety disorder (aRR, 2.71; 95% CI, 2.59-2.84), and obsessive-compulsive disorder (aRR, 3.14; 95% CI, 2.70-3.66).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: heritability and polygenic associations in UK primary care cohorts
“In UKB, TRD vs healthy controls and non-TRD vs healthy controls h2SNP was comparable (0.25 [SE = 0.04] and 0.19 [SE = 0.02], respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TRD vs non-TRD was positively associated with the PRS of attention deficit hyperactivity disorder, with lower socio-economic status, obesity, higher neuroticism and other unfavourable clinical characteristics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: baseline predictors in US commercial claims
“TRD patients at baseline were younger; 10.87% were between 18 and 19 years old versus 7.64% in the no‐TRD group, risk ratio (RR) = 1.42 (95% confidence interval [CI] 1.37–1.48).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 3.68, fatigue had the highest RR (95% CI 3.18–4.25). TRD patients had substance use disorders, psychiatric conditions, insomnia, and pain more often at baseline than non‐TRD patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: sociodemographic characteristics
“It is established that older persons more frequently fail multiple monoamine‐based antidepressant treatments, which may be taken as evidence that TRD is more common in this subpopulation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is not established whether female sex is a risk factor for TRD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Socioeconomic position is a risk factor for TRD in persons receiving monoamine‐based antidepressants. For example, in the STAR*D trial, persons meeting level 2 criteria (i.e., inadequate response to two sequential antidepressant regimens) were more likely to report lower income and dependence on the public health system” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: childhood maltreatment and life stress
“There are also studies providing evidence that a reported history of childhood emotional abuse is associated with recurrent depression, persistent depression, as well as treatment resistance to antidepressants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The international Study to Predict Optimized Treatment for Depression (iSPOT‐D) reported that, amongst adults with MDD and a history of trauma between the ages of 4 and 7 years, only 15.9% achieved remission after 8 weeks of treatment with escitalopram, sertraline or venlafaxine, compared to 84.1% in individuals with no history of childhood trauma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: illness severity, episode duration, and clinical features
“Greater baseline severity is a highly replicated risk factor for TRD, and is indeed included in some frameworks as a variable in the hierarchical characterization of the condition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Illness duration is also highly associated with TRD, with replicated evidence indicating that the length of a depressive episode is inversely proportional to the probability of treatment response” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Psychotic symptoms affect approximately 20% of adults with MDD and are highly associated with TRD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results from the STAR*D trial indicate that persons presenting with anxious depression exhibit attenuated antidepressant response and are more likely to develop TRD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Treatment-resistant depression
United States commercial, Medicaid, and Medicare claims: incidence by operating definition
“Incidence/100,000 cohort members/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Truven MarketScan Commercial Claims and Encounters (CCAE), with approximately 35 million mainly privately insured subscribers in 2011; Truven MarketScan Medicaid (MDCD), a means-tested public insurance program with approximately 5 million subscribers in 2011, and Truven MarketScan Medicare Supplemental Beneficiaries (MCDR), a public insurance program that is not means-tested, with approximately 3 million subscribers in 2011, most of whom were aged 65 or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we defined TRD as failure of two medications as evidenced by their replacement or supplementation by other medications, and set maximum durations (caps) for how long a medication regimen could remain in use and still be eligible to fail.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TRD incidence estimates varied approximately 2-fold between the two databases (CCAE, Medicaid) that described socioeconomically different non-elderly populations; for a given cap varied 2-fold to 4-fold within each database across the other implementation choices; and if the cap was also allowed to vary, varied 6-fold or 7-fold within each database.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“among such studies the proportion of PTD cases that develop into TRD cases ranges from 35% in a study limited to PTD subjects with a diagnosis of MDD [9] to less than 10% in a study that included a wider range of depression diagnoses among the PTD subjects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States commercial claims: progression to TRD within 1 year of newly treated depression
“The outcome was TRD, defined as having at least three distinct antidepressants or one antidepressant and one antipsychotic within 1 year after the index date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 230,801 included patients, 10.4% developed TRD within 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States commercial claims: treated depressive episodes meeting TRD criteria
“Episodes of these patients in which there were at least two distinct failed regimens involving antidepressants and antipsychotics were classified as TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the treated episodes, 6.6% (N = 3,134) met the criteria for TRD. The median time to an episode becoming TRD was approximately one year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States commercial claims: treated MDD meeting TRD criteria during follow-up
“Patients who started a third AD regimen after two regimens of appropriate duration were included in the TRD cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Out of 355,942 patients with MDD, 34,176 (9.6%) met the criterion for TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sweden, Stockholm region: depressive episodes progressing to TRD
“A total of 158 169 unipolar MDD episodes (in 145 577 patients) were identified between January 1, 2012, and December 31, 2017 (64.7% women; median [IQR] age, 42 years [30-56]). Of these, 12 793 episodes (11%) fulfilled criteria for TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median (IQR) time from the start of MDD episode to TRD was 552 days (294-932).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
France, national claims sample: annual incidence and prevalence
Prevalence of Treatment-resistant depression
United States: 12-month prevalence of TRD among adults with medication-treated MDD
“Prevalence and health care burden of TRD were estimated by synthetizing inputs across 4 similarly designed claims studies in adults covered by Medicare, Medicaid, commercial plans, and the US Veterans Health Administration (VHA).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated 12-month prevalence of medication-treated MDD in the United States was 8.9 million adults, and 2.8 million (30.9%) had TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: TRD population cited in the ICER draft scope
United States: past-year major depressive episode among adults, NSDUH 2025
United States: 12-month and lifetime prevalence of DSM-5 MDD, NESARC-III
United States: cumulative remission across four treatment steps, Sequenced Treatment Alternatives to Relieve Depression trial
United States: Sequenced Treatment Alternatives to Relieve Depression trial participants without remission after two treatment trials
“In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, a third of patients did not achieve remission or adequate response after two treatment trials, fulfilling requirements for treatment resistant depression (TRD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: estimate based on the Sequenced Treatment Alternatives to Relieve Depression trial under FDA and EMA criteria, and range across settings
“TRD is often stated to affect approximately 30% of persons receiving antidepressant treatment in research settings, while its prevalence in real world practice is estimated to range between 6 and 55%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The FDA and EMA definitions of TRD would align with failure to level 1 and 2 treatments in the STAR*D trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In summary, while it is often stated that TRD is affecting approximately 30% of persons receiving antidepressant treatment, a more stringent and multidimensional definition of this condition emphasizing symptomatic remission increases this estimate to about 55%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States commercial claims: share of treated depression meeting a data-driven TRD rule
United Kingdom primary care: patients on repeat antidepressant prescriptions
“Those who scored ≥14 on the BDI-II and had taken antidepressants for at least 6 weeks at an adequate dose were defined as treatment resistant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty-five per cent (95% CI = 53% to 58%) (n = 1177) met the study’s definition of TRD, of whom 67% had taken their antidepressants for more than 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Canada primary care: consecutive patients with MDD
“Using failure to respond to at least 2 antidepressants (ADs) from different classes as the definition of TRD, the overall prevalence was 21.7%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence across provinces varied (P < 0.001), with British Columbia having the highest rate (28.7%) and Alberta the lowest rate (12.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United Kingdom primary care records: UK Biobank and EXCEED
Scotland and UK Biobank health records: proportion by definition
Sweden, national registers: antidepressant initiators classified with TRD
“Patients with at least two additional treatment trials during the same depressive episode were classified as having TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In total 15,013 patients (13%) were classified with TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
France, national claims sample: annual prevalence
Natural history, survival, and mortality
Course: relapse and recovery in medium- to long-term outcome studies
“We identified nine outcome studies with a total of 1279 participants and follow-up duration of between 1 and 10 years. In the short term, TRD was highly recurrent with as many as 80% of those requiring multiple treatments relapsing within a year of achieving remission. For those with a more protracted illness, the probability of recovery within 10 years was about 40%. TRD was also associated with poorer quality of life and increased mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Course: relapse by number of treatment steps, Sequenced Treatment Alternatives to Relieve Depression trial
“Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Course: two-year outcomes under treatment as usual
“The 12- and 24-month IDS-SR-30 response rates were 11.6% (13/112) and 18.4% (19/103), respectively. Of the 13 responders at 12 months, only 5 were responders at 24 months. The 12- and 24-month IDS-SR-30 remission rates were 3.6% (4/112) and 7.8% (8/103), respectively. Only 1 of the 4 12-month remitters was also a remitter at 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the wide range of treatment options available for depression, the response rates, remission rates, and quality-of-life results in this study show that most patients with a substantial degree of treatment resistance continue to have significant symptomatology and functional disability when receiving TAU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Course: episode duration in US commercial claims
Course: time between treatment trials in the Stockholm cohort
“Median time from start of the first antidepressant treatment to start of the second, and from start of the second antidepressant treatment to start of the third, was 165 and 197 days, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Episode duration was longer in the TRD group than in the non-TRD group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
All-cause mortality: US commercial claims
“TRD was associated with a significantly higher mortality compared with non-TRD MDD (adjusted HR: 1.29; 95% CI 1.22–1.38; p < 0.0001). Survival time was significantly shorter in the TRD cohort compared with the non-TRD MDD cohort (p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
All-cause and external-cause mortality: Swedish national registers
“Adjusted HR for all-cause mortality was 1.35 (95% CI 1.21-1.50). Mortality from external causes (including suicides and accidents) was markedly higher in TRD patients than in other depressed patients (HR 1.97; 1.69-2.29), while mortality from non-external causes was similar. The adjusted EMRR was 1.52 (1.31-1.76), highest among patients 18-29 years old (EMRR 2.03; 1.31-1.76) and patients without somatic comorbidity (EMRR 1.99; 1.63-2.43).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
All-cause mortality: Stockholm MDD cohort
“The all-cause mortality rate for patients with MDD with TRD episodes was 10.7/1000 person-years at risk, compared with 8.7/1000 person-years at risk for patients with MDD without TRD episodes (hazard ratio, 1.23; 95% CI, 1.07-1.41).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Excess deaths: Swedish national registers
“Compared with the mortality risk of other depressed patients, patients with TRD experienced excess deaths in most age and comorbidity categories in the range of 7–16 deaths per 1000 patients during 5 years. Highest numbers for all-cause excess deaths were found among patients 18–29 years old with CCI 1, where 16 [95% confidence interval 5–28] of the expected 37 [25–48] deaths per 1000 patients were excess deaths. The majority of the excess deaths were due to external causes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicide mortality: US commercial and Medicare claims linked to the National Death Index
“For the 139,753 TRD, 85,602 MDD+SI/SA, and 572,098 MDD alone cohort patients, mean age ranged from 55 to 59 years and the majority were female.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Suicide‐mortality rates in the three cohorts were 0.14/100 person‐years for TRD, 0.27/100 person‐years for MDD+SI/SA, and 0.04/100 person‐years for MDD alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicide and suicide attempts: meta-analysis of TRD samples after treatment initiation
“Thirty percent of patients with treatment-resistant depression (TRD) attempt suicide at least once during their lifetime.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall incidence of completed suicides was 0.47 per 100 patient years (95% CI: 0.22-1.00), and of attempted suicides 4.66 per 100 patient years (95% CI: 3.53-6.23). No differences were found in incidences following DBS, VNS or ECT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Suicide and suicide attempts: risk factors in Swedish national registers
“In all, 178 patients died by suicide and 1,242 experienced a suicide attempt during follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“History of suicide attempts, especially if <1 year after the attempt, was a significant independent risk factor for suicide (adjusted odds ratio [aOR], 8.9; 95% confidence interval [CI], 5.1-15.7) as were 10 to 12 years of education compared to lower education (aOR, 1.69; 95% CI, 1.02-2.81).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intentional self-harm: Stockholm MDD cohort
Pathophysiology
Overview: limited distinction from treatment-responsive depression
“TRD patients exhibit the same diversity of symptoms, course, history and co-occurring conditions as for treatment-responsive MDD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It must be emphasized that the following mechanisms and etiological processes have not yet been compared sufficiently between TRD versus treatment-responsive MDD. Establishing areas of similarities and differences between the two is a high priority of current research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Stress response: hypothalamic-pituitary-adrenal axis
“Studies of the neurobiology of depression, including TRD, focus largely on the association between stress and depression, with the hope that an understanding of the biological pathways that link stress to depression would inform on the pathophysiology of the disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Altered functioning of the hypothalamic-pituitary-adrenal (HPA) axis has been demonstrated in patients with treatment-resistant depression, although studies have often conflated patients with unipolar and bipolar depression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with TRUD had higher total cortisol production in the morning hours compared to controls (AUCg, p = 0.01), while they did not differ in terms of the awakening response (AUCi, p = 0.28).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inflammation: peripheral C-reactive protein
“Compared with healthy volunteers, BMI-corrected CRP was significantly elevated in the treatment-resistant group (P = 0.007; Cohen's d = 0.47); but not significantly so in the treatment-responsive (d = 0.29) and untreated (d = 0.18) groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CRP was elevated in patients with MDD, and more so in treatment-resistant patients. Other phenotypes associated with elevated CRP included childhood adversity and specific depressive and anxious symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glutamate signaling and glial cells
“Although excessive glutamatergic neurotransmission and consequent excitotoxicity were considered a major cause of TRD, recent evidence suggests that the extrasynaptic glutamatergic receptor signal pathway mainly contributes to the detrimental effects of TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Glial cells such as microglia and astrocytes, early life adversity, and glucocorticoid receptor dysfunction participate in complex cross-talk.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Excessive microglial activation and the inflammatory process cause astrocyte glutamatergic dysfunction, which in turn activates microglial function.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Brain networks: neuroimaging differences between TRD and non-TRD
“Our main findings are that patients with TRD show 1) reduced functional connectivity (FC) within the default mode network (DMN), 2) reduced FC between components of the DMN and other brain areas, and 3) hyperactivity of DMN regions. In addition, aberrant activity and FC in the occipital lobe may play a role in TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The main limitations of most studies were related to inherent confounding factors for comparing TRD with non-TRD, such as differences in disease chronicity/severity and medication history.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Diagnostic assessment: structured interview and treatment history instruments
“At a minimum, assessment to define TRD should include a structured clinical interview for the diagnosis of MDD, such as the Structured Clinical Interview for DSM (SCID) [53, 54] and the Mini-International Neuropsychiatric Interview (MINI) [55], together with a scale to assess the patient’s antidepressant history, such as the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) [56], and the Antidepressant Treatment History Form (ATHF) [57]. A more structured method is to use staging models [6, 58], such as the Thase and Rush method [59], the Massachusetts General Hospital Staging model (MGH-s) [22], and the more recent Maudsley Staging Model (MSM) [60], which also allows the assessment of previous antidepressant treatment failure, using the Maudsley Treatment Inventory (MTI) [10].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the experts, there was a substantial agreement that staging models are the preferred instrument to define TRD/PRD and assess the level of treatment-resistance, even if many experts recognize the validity of the ATRQ, often accepted in regulatory clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Confirming treatment resistance: retrospective assessment and screening for bipolarity
Confirming treatment resistance: excluding pseudo-resistance
“Reviewed herein are the most common modifiable contributors to pseudo‐resistance, including inaccuracy of the MDD diagnosis, inadequacy of current and past treatment trials, inaccurate assessment of response, and individual differences in the metabolism of antidepressants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaccuracy of the MDD diagnosis is a common reason for pseudo‐resistance. It is estimated that approximately half of individuals with MDD are not correctly diagnosed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, it is reported that the transition from a diagnosis of MDD to one of bipolar disorder occurs at a rate of approximately 1‐3% per year, indicating that diagnostic assessment must be reconsidered in all TRD presentations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The adequate duration of an antidepressant trial is generally considered to be 4‐6 weeks at optimal dosing, although 60% of persons who achieved remission in the STAR*D trial with level 1 treatment did so after week 6 of treatment, indicating that a subpopulation of adults with MDD may require longer treatment trials” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using this definition, about 30‐50% of persons prescribed with antidepressants are non‐adherent in acute phase treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although pharmacogenetic testing cannot be recommended as a routine assessment in TRD, some preliminary evidence does suggest that, in select circumstances, it may be warranted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, determining the adequacy of prior treatment is essential since substantial evidence indicates that large numbers of depressed patients are undertreated, resulting in prolonged episodes and the appearance of "pseudoresistance."” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Guideline recommendation: reassessment after poor response
“The first steps in the assessment of poor response involve re-evaluating the diagnosis (e.g., a missed diagnosis of bipolar disorder), comorbidities, and adherence to treatment. In addition to clinical reassessment, laboratory investigations should be considered to rule out potential medical factors that can contribute to persistent symptoms and that require additional interventions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A diagnostic re-evaluation is essential to the proper management of these patients. In particular, the potential role of several contributing factors, such as medical and psychiatric comorbidity, needs to be taken into account.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Staging models: Thase and Rush model
“In this paper, alternate antidepressant strategies are reviewed within the context of a five-stage strategy, ranging from lesser to greater degrees of treatment resistance. The overall strategy recommended progresses from simpler (i.e., an alternate monotherapy) to more complex strategies (i.e., combination or augmentation regimens), with the nonselective monoamine oxidase inhibitors (+/- lithium salts) and electroconvulsive therapy typically reserved for treatment of Stages III and IV of resistance, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Stage I is defined by failure of at least one adequate trial of one major class of antidepressants; stage II by failure of at least two adequate trials of at least two distinctly different classes of antidepressants; stage III by stage II resistance plus failure of an adequate trial of a tricyclic antidepressant (TCA); stage IV by stage III resistance plus failure of an adequate trial of a monoamine oxidase inhibitor (MAOI); and stage V by stage IV resistance plus failure of a course of bilateral electroconvulsive therapy (ECT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Staging models: Maudsley Staging Method
“We present a points-based staging model incorporating 3 factors: treatment, severity of illness, and duration of presenting episode. In this model, the rating of symptom severity ranges from subsyndromal depression (score 1) to severe syndromal depression with psychosis (score 5). Antidepressant treatment is rated on a 5-point subscale based on number of medications used, while duration of the presenting episode is rated on a 3-point subscale. The overall level of resistance estimated using this model varies from minimal resistance (score of 3) to severe resistance (score of 15).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The core dimension of the MSM, treatment failure, may be assessed using the Maudsley Treatment Inventory (MTI), a new method developed for the purposes of completing the MSM. The MTI consists of a relatively comprehensive list of medications with options for rating doses and provisions treatment for multiple episodes. The second dimension, severity of symptoms, may be assessed using simple instruments such as the Clinical Global Impression, the Psychiatric Status Rating or checklist from a standard diagnostic checklist. The standardisation also provides a simple rating scale for scoring the third dimension, duration of depressive episode.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Staging models: Massachusetts General Hospital model
“One point is assigned for non‐response to each adequate trial of a marketed antidepressant (duration of at least six weeks and adequate dosage). Half a point is assigned for each trial based on optimization of dose, optimization of duration, or an augmentation/combination strategy. Three points are assigned for non‐ response to ECT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Staging models: systematic review of five models
“From 950 retrieved articles five staging models were found; the Antidepressant Treatment History Form, Thase and Rush Model, European Staging Model, Massachusetts General Hospital Staging model and the Maudsley Staging Model (MSM). Six studies investigated the predictive utility (of four models). We observed an evolution from single antidepressant adequacy ratings, towards a multidimensional and more continuous scored staging model which also introduced TRD characteristics (severity and duration). The operationalization criteria improved; the scoring of different treatment strategies (between/within class switching and augmentation/combination) changed according to the existing evidence. Over time, efforts to validate models improved. The predictive utility was assessed best for the MSM.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Few staging models existed; their reliability was hardly assessed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rating scales: instruments accepted for trials
“We recommend (with moderate consensus) that the clinician administered MADRS10 is the preferred outcome instrument to assess treatment response (and remission) (85%), together with patient-reported QIDS-SR (81%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rating scales: Montgomery-Åsberg Depression Rating Scale development
“Ratings on these 17 items for 64 patients participating in studies of four different antidepressant drugs were used to create a depression scale consisting of the 10 items which showed the largest changes with treatment and the highest correlation to overall change.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rating scales: response, nonresponse, and remission thresholds
“Early improvement is often defined with a symptom scale as a reduction in score of 20% or greater from baseline (within 2 to 4 weeks after treatment initiation), whereas response is defined as 50% or greater improvement from baseline. Symptom remission is indicated by a specific threshold score for each scale, e.g., a score of 7 or less on the Hamilton Depression Rating Scale (HAM-D), 10 or less on the Montgomery-Åsberg Depression Rating Scale (MADRS), and 4 or less on the PHQ-9.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An exception is the GSRD staging method 14 , which explicitly defines treatment non‐response as a reduction of less than 50% in the total score on the HAM‐D or the MADRS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%. If a state of almost complete absence of symptoms were required for a definition of remission, a MADRS total score would be <8, because such scores corresponded to a CGI-S score of 2 ('borderline mentally ill').” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Mood symptoms: depressed mood and loss of interest or pleasure
Symptom clusters: mood, insomnia, somatic, and anxiety symptoms in TRD
Somatic and neurovegetative symptoms: fatigue, insomnia, and pain before TRD onset
“Ten percent of subjects newly diagnosed and treated for depression developed TRD within a year. They were younger and suffered more frequently from fatigue, substance use disorders, anxiety, psychiatric conditions, insomnia, and pain than non‐TRD patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cognitive symptoms: deficits in multiple cognitive domains
“Cognitive deficits in MDD are prevalent, persistent, and often progressively increase as a function of illness severity and duration; they are associated with attenuated response to select antidepressants, and may represent a risk factor for TRD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety symptoms: anxious depression and comorbid anxiety disorders
“Anxiety symptoms are frequently reported in TRD populations, and their presence in MDD is associated with a more severe illness presentation, lower probability of remission, comorbidities and suicidality” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, anxiety disorders were present in 53.92%, 44.11%, and 21.72% of patients with TRD, MDD+SI/SA, and MDD alone, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two hundred fifty-three patients, who had at least one post-baseline Montgomery-Asberg Depression Rating Scale and Hamilton Depression Rating Scale score were included in the analysis. Of them, 182 subjects presented anxious and 71 nonanxious depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychotic and mixed features
“Mixed features are reported to be present in approximately 25% of persons with MDD and are associated with attenuated antidepressant response, although it remains to be determined whether they are a risk factor specifically for TRD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicidal ideation and hopelessness
“More than half of patients reported thoughts or wishes of death to self and significant hopelessness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with TRD are more likely than not to report prominent suicidal ideation and hopelessness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Functional impairment: work, social functioning, and quality of life
“During follow-up, TRD patients had lower health-related quality of life (HRQOL) scores on mental (30 vs 45.7) and physical components (47.7 vs 48.9) of the SF12, and lower Q-LES-Q scores (43.6 vs 63.7), greater functional and work impairments and productivity loss vs non-TRD patients (all p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Residual symptoms after treatment
Long-term morbidity
Physical comorbidity: incident cardiovascular and metabolic disease
“It is well established that TRD populations have a higher rate of psychiatric and physical comorbidities as compared to non‐TRD populations 143 . In addition, TRD is a risk factor for incident physical comorbidities, such as cardiovascular disease, type 2 diabetes mellitus, osteoporosis, and metabolic syndrome” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, it is established that MDD is a risk factor for cardiovascular disease, obesity and type 2 diabetes mellitus, and this is especially apparent in individuals with more severe and/or persistent depressive syndromes, which are over‐represented in TRD populations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular events: major adverse cardiovascular events in Swedish registers
“We identified 143,731 patients with depression, including 23,335 with TRD and 45,217 with severe depression. Patients with depression had a higher hazard of MACE vs comparators (aHR 1.50, 95%CI 1.40-1.62). Hazards of MACE were overall similar in patients with TRD vs comparators (aHR 1.06, 95%CI 0.93-1.22) and severe depression vs comparators (aHR 1.04, 95%CI 0.96-1.13). Analyzing separate outcomes, patients with TRD had a higher hazard of cardiovascular death (aHR 1.32, 95 %CI 1.03-1.69).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with TRD or severe depression are not at additional overall risk of MACE compared to other depressed patients. However, an additional risk may exist in younger patients with severe depression and specifically of cardiovascular death in patients with TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric comorbidity: Stockholm MDD cohort
“In patients with TRD, we observed a gradual increase in the prevalence of all psychiatric comorbid diagnoses during the year preceding the TRD index date, most pronounced for anxiety and stress (60% and 36%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Table 1 also shows an increased prevalence for sleep disorders, substance abuse, personality disorders, and intentional self-harm in patients with TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity, obesity, and disability: Canadian primary care
Work disability: lost workdays in the Stockholm MDD cohort
“Compared with matched non-TRD episodes, TRD episodes had more inpatient bed-days (mean, 3.9 days; 95% CI, 3.6-4.1, vs 1.3 days; 95% CI, 1.2-1.4) and more lost workdays (mean, 132.3 days; 95% CI, 129.5-135.1, vs 58.7 days; 95% CI, 56.8-60.6) 12 months after the index date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life and functional disability under usual care
Burden of Treatment-resistant depression
Humanistic burden and health-related quality of life
Quality of life, functioning, and work productivity in TRD versus non-TRD MDD: Sequenced Treatment Alternatives to Relieve Depression trial secondary analysis
“A total of 2467 (TRD: 377; non-TRD: 2090) patients were studied.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During follow-up, TRD patients had lower health-related quality of life (HRQOL) scores on mental (30 vs 45.7) and physical components (47.7 vs 48.9) of the SF12, and lower Q-LES-Q scores (43.6 vs 63.7), greater functional and work impairments and productivity loss vs non-TRD patients (all p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-5L utility and work productivity in TRD versus non-TRD MDD: United Kingdom non-interventional study
“148 patients with clinician-verified symptomatic (non-treatment-resistant) MDD (Patients-MDD; n = 61) or TRD (Patients-TRD; n = 87) were recruited from ten clinical sites.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, HRQoL was significantly poorer for Patients-TRD compared with Patients-MDD, both in the overall cohort (median EQ-5D-5 L utility 0.606/0.721, respectively [p = 0.021]; WHOQOL-BREF overall score 55.2/58.8 [p = 0.024]) and in patients with a PHQ-9 score ≥15 (median EQ-5D-5 L utility 0.415/0.705, respectively [p<0.001]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although a numerically lower proportion of Patients-TRD were employed (45% vs 57% of Patients-MDD; p = 0.204), employed Patients-MDD reported significantly higher absenteeism and work productivity loss.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-5L, SF-12v2, and work and activity impairment versus non-TRD depression and the general population: five European countries
“A total 52,060 survey respondents were examined, of which 2686 and 622 were considered to have non-treatment resistant and treatment-resistant depression, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to the general population, nTRD and TRD respondents reported significant decrements in health-related quality of life, including lower adjusted mental (− 12.1 vs. -18.1) and physical (− 2.5 vs. -5.4) component scores of the SF-12v2 and increased adjusted relative risk for work (2.2 vs. 2.7) and activity (1.9 vs. 2.5) impairment (all p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for demographics and health characteristics, TRD and nTRD groups had poorer health status as assessed by the EQ-5D-5 L (− 0.329 and − 0.173, respectively, both p < 0.001) and EQ-VAS (− 27.440 and − 16.724, respectively, both p < 0.001) compared to the general population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-5L, employment, and work productivity at treatment initiation: European real-world TRD cohort
“Overall, 411 eligible patients were enrolled across seven European countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term sick leave was reported by 19.0% of patients; 30.2% were unemployed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, mean (SD) HRQoL scores for EuroQoL 5-dimension 5-level (UK tariff) and EQ-Visual Analog Scale were 0.41 (0.25) and 41.1 (18.7), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The Work Productivity and Activity Impairment questionnaire demonstrated mean (SD) absenteeism of 57.0% (44.9%) and presenteeism of 54.7% (29.5%); mean (SD) overall work impairment was 60.5% (29.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Proportion reporting problems on each EQ-5D-5L dimension at baseline: esketamine phase 3 trial population
“The full analysis set included 223 patients (ESK + AD: 114; AD + PBO: 109; mean [SD] age: 45.7 [11.89]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| EQ-5D-5L dimension | Esketamine plus antidepressant group at baseline, % | Antidepressant plus placebo group at baseline, % |
|---|---|---|
| Mobility | “28.1”View highlighted excerpt for this quote | “34.9”View highlighted excerpt for this quote |
| Self-care | “53.5”View highlighted excerpt for this quote | “53.2”View highlighted excerpt for this quote |
| Usual activities | “94.8”View highlighted excerpt for this quote | “92.7”View highlighted excerpt for this quote |
| Pain/Discomfort | “68.5”View highlighted excerpt for this quote | “74.3”View highlighted excerpt for this quote |
| Anxiety/Depression | “98.3”View highlighted excerpt for this quote | “99.9”View highlighted excerpt for this quote |
Quality-of-life decrement versus remission or response: systematic review of United States data, 1996 to 2013
“Sixty-two articles were included (N=59,462 patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Quality-of-life scores (scale of 0-1, with 0 indicating death and 1 indicating perfect health) for patients with treatment-resistant depression were .41±.8 and .26±.8 points lower, respectively, than for patients who experienced remission or response.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life across increasing levels of non-response: systematic review
“Likewise, the 19 studies studying HRQoL burden found that increasing levels of TRD/non-response correlated with reduced patient HRQoL and health status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A consistent trend was observed such that medical costs increased and patient HRQoL and health status decreased by increasing level of TRD/non-response within an MDD episode.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health state utilities by depression severity used in a United States cost-effectiveness model of esketamine
Economic burden and healthcare resource utilization
National annual burden of TRD within medication-treated MDD in the United States
“The estimated 12-month prevalence of medication-treated MDD in the United States was 8.9 million adults, and 2.8 million (30.9%) had TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The total annual burden of medication-treated MDD among the US population was $92.7 billion, with $43.8 billion (47.2%) attributable to TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The share of TRD was 56.6% ($25.8 billion) of the health care burden, 47.7% ($8.7 billion) of the unemployment burden, and 32.2% ($9.3 billion) of the productivity burden of medication-treated MDD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incremental societal economic burden of MDD in the United States in 2019
“In 2019, the number of adults with MDD in the USA was estimated at 19.8 million (62.7% female; 32.9% severe MDD), and the incremental societal economic burden of MDD was estimated at $333.7 billion ($382.4 billion in 2023 US dollars), or $16,854 per adult with MDD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary cost drivers were healthcare costs ($127.3 billion; 38.1%), household-related costs ($80.1 billion; 24.0%), presenteeism ($43.3 billion; 13.0%), and absenteeism ($38.4 billion; 11.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the simulated scenario, a hypothetical novel therapy with a 50.0% early response rate was associated with a 7.7% reduction in the economic burden of MDD relative to standard of care over 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Commercially insured adults: health care costs, work loss, and employment status change
“TRD patients (N = 6,411) had more HRU than either matched control cohort, translating into higher per patient per year (PPPY) health care costs: $6,709 and $9,917 more than non-TRD MDD and non-MDD patients, respectively (P < .001 for both).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TRD patients with work loss data (N = 1,908) had 35.8 work loss days PPPY (1.7 and 6.2 times the work loss rate in non-TRD MDD and non-MDD patients, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Work loss-related costs in TRD patients were $1,811 higher than non-TRD MDD and $3,460 higher than in non-MDD patients (P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TRD patients had 1.3-1.4 times the rate of employment status change versus control cohorts (all P < .05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Commercially insured adults with physical conditions: resource use, health care costs, and work loss
“A total of 2,317 patients with TRD (mean age, 47.6 years; 63.1%, female; mean follow-up, 19.7 months) had ≥ 1 co-occurring key physical condition (cardiovascular, 52.5%; metabolic, 48.2%; respiratory, 16.4%; and cancer, 9.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to non-TRD MDD and non-MDD cohorts, respectively, patients with TRD had 46% and 235% more inpatient admissions, 28% and 128% more emergency department visits, and 53% and 155% more outpatient visits (all P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Health care costs were $22,541 in the TRD cohort, $17,450 in the non-TRD MDD cohort, and $10,047 in the non-MDD cohort, yielding cost differences of $5,091 (vs. non-TRD MDD) and $12,494 (vs. non-MDD; all P < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with work loss data available (n = 278/cohort), those with TRD had 2.0 and 2.9 times more work loss as well as $8,676 and $10,323 higher work loss costs relative to those with non-TRD MDD and without MDD, respectively (all P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Commercially insured employees: direct and indirect costs over 2 years
“Employees who initiated a third antidepressant following two antidepressant treatments of adequate dose and duration or who met published TRD criteria were classified as TRD likely (N = 2312).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Average direct 2-year costs were significantly higher for TRD-likely employees ($22,784) compared with MDD controls ($11,733), p < 0.0001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Average indirect costs were also higher among TRD-likely employees ($12,765) compared with MDD controls ($6885), p < 0.0001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Commercially insured adults: episode duration and total costs of TRD episodes
“Of all episodes, 7% were TRD, with a mean duration of 571 (285) days vs. 200 (198) days for non-TRD MDD episodes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean total all-cause costs were $19,626 ($44,160) for TRD and $7440 ($25,150) for non-TRD MDD episodes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare beneficiaries: resource use and health care costs
“Of these, 3,224 (10.9%) met the study definition of TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the observation period, the total all-cause PPPY healthcare costs were $25,059 in the TRD cohort, $19,945 in the non-TRD MDD cohort, and $14,410 in the non-MDD cohort (all P<0.001; Fig 3 and Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TRD cohort had significantly higher adjusted PPPY all-cause healthcare costs versus the non-TRD MDD (adjusted cost difference = $3,377, P<0.001) or non-MDD cohorts (adjusted cost difference = $3,675, P<0.001; Fig 3 and Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TRD cohort had higher rates of PPPY behavioral health-related HRU relative to the non-TRD MDD cohort (e.g., inpatient visits: IRR = 1.49) and versus the non-MDD cohort (e.g., inpatient visits: IRR = 3.84, all P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare beneficiaries: published correction of the abstract results
“In the Results subsection of the Abstract. there are numbers reported which are inconsistent with those of the main text.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TRD cohort had significantly higher total PPPY healthcare costs than the non-TRD MDD cohort ($25,059 vs. $19,945, adjusted cost difference = $3,377) and non-MDD cohort ($25,059 vs. $14,410, adjusted cost difference = $3,675, all P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare beneficiaries aged 65 years or older: resource use, costs, and hospitalization risk
“After matching, 178 patients from each cohort were analyzed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During 12 months of follow-up, TRD patients had higher use of different antidepressants and antipsychotics, higher inpatient and emergency room visits, longer inpatient stays, and higher total healthcare costs ($24,543 versus $16,059, $8,058) than non-TRD MDD and non-MDD cohorts, respectively (all p <0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Risk of initial hospitalization was higher in the TRD (hazard ratio [HR] = 3.60, 95% confidence interval [CI] = 2.08-6.23) and non-TRD MDD cohorts (HR = 1.82, 95% CI = 1.02-3.25) than the non-MDD cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicaid beneficiaries: resource use and costs
“TRD beneficiaries had higher HRU than 1:1 matched non-TRD-MDD (e.g., inpatient visits: IRR = 1.41) and non-MDD beneficiaries (N = 14,710 per cohort; e.g., inpatient visits: IRR = 3.42, p < 0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TRD beneficiaries incurred greater costs versus non-TRD-MDD (CD = US$4382) and non-MDD beneficiaries (CD = US$8294; p < 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicaid beneficiaries initiating esketamine, electroconvulsive therapy, or transcranial magnetic stimulation: mental health-related resource use and costs
“ESK cohort included 151 patients (mean age: 40.6 years; female: 70.2%), ECT cohort included 198 patients (mean age: 43.0 years; female: 60.6%), and TMS cohort included 140 patients (mean age: 39.5 years; female: 65.0%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean MH-related acute care costs during the follow-up period trended lower in ESK cohort (IP: $76; ED: $29) relative to ECT (IP: $1,547; ED: $45) and TMS cohorts (IP: $238; ED: $123).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Outpatient costs in ESK cohort ($1,632) exceeded OP costs in ECT ($1,023) and TMS ($1,051) cohorts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This finding should be interpreted with caution, given potential differences in patient profiles, clinical history and setting of administration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Veterans Health Administration: resource use and health care costs
“After 1:1 exact matching, 10,449 patients were included in each cohort (mean age: 48.9 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with TRD had higher per patient per year (PPPY) HRU than non-TRD MDD (all-cause inpatient visits: incidence rate ratio [IRR]: 1.70 [95% confidence interval: 1.57-1.83]) and non-MDD (IRR: 5.04 [95% confidence interval: 4.51-5.63]), and incurred higher total all-cause health care costs PPPY than non-TRD MDD (mean difference: $5,906) and non-MDD (mean difference: $11,873; all p<.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incremental health care and productivity costs across studies: systematic review of United States data, 1996 to 2013
“Annual costs for health care and lost productivity were $5,481 and $4,048 higher, respectively, for patients with treatment-resistant versus treatment-responsive depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At current rates of 12%-20% among all depressed patients, treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs across increasing levels of non-response: systematic review
Inpatient bed-days, outpatient visits, and lost workdays: population-based cohort in Stockholm, Sweden
“Of these, 12 793 episodes (11%) fulfilled criteria for TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with matched non-TRD episodes, TRD episodes had more inpatient bed-days (mean, 3.9 days; 95% CI, 3.6-4.1, vs 1.3 days; 95% CI, 1.2-1.4) and more lost workdays (mean, 132.3 days; 95% CI, 129.5-135.1, vs 58.7 days; 95% CI, 56.8-60.6) 12 months after the index date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This cohort study found that, compared with patients with MDD and no TRD episodes, patients with TRD episodes had higher prevalence of psychiatric comorbid conditions, twice the utilization of outpatient health care resources, 3 times the number of inpatient bed-days, and 23% higher all-cause mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health care professional visits versus the general population: five European countries
“Additionally, healthcare resource utilization was significantly higher for TRD patients more so than nTRD, compared to the general population, especially for healthcare professional visits (odds ratio nTRD = 5.4; TRD = 15.9, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Treatment-resistant depression on families
Indirect and direct costs for employed caregivers of persons with TRD: national population-based survey
“Screening identified 169 TRD caregivers and 1070 No TRD caregivers providing 23.3 and 14.6 mean weekly caregiving hours, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjusted annual indirect cost estimates were $11,121 for caregivers of TRD and $7761 for caregivers in the No TRD group (P ≤ 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At-work productivity loss (presenteeism) was the largest component.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjusted annual direct cost estimates were $29,805 for caregivers of TRD and $20,642 for caregivers in the No TRD group (P ≤ 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver work absences, reduced hours, leave, and out-of-pocket expenses
“Caregiving-related work absences were higher in the TRD group (5.0 days vs 3.2 days).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A larger proportion of caregivers in the TRD group reduced their work hours (29.0% vs 11.5%), resulting in an unadjusted, annualized cost of $1369 versus $512 (P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, the proportion taking a leave of absence was higher in the TRD group as well (11.1% vs 5.2%), resulting in a difference in the unadjusted annualized cost ($4367 vs $1047; P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of caregivers in the TRD group with out-of-pocket expenses for caregiving services was double the rate of the No TRD group (45.5% vs 22.2%; P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the TRD group, the percentage of caregivers who were spouses or partners to care recipients was twice as high as the No TRD group (27.8% vs 12.7%); (difference in relationship type P ≤ 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver mental health and study limitations
“Caregivers in the TRD group also reported more frequent depression symptoms of anhedonia (ie, loss of the capacity to experience pleasure) and depressed mood (P ≤ 0.0001), and 16.8% versus 6.7% screened positive for depression (P ≤ 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It was cross-sectional and the sample, though large, was a convenience sample.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This was the first time that self-report has been used to operationalize the TRD criteria, and though following rigorous survey methods, the assessment tool was not tested for reliability and validity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Income loss among household members of adults with MDD in the United States in 2019
“An estimated 17 million adults without MDD live in a household with an adult with MDD and the total incremental loss in annual income among these individuals was estimated at $80.1 billion ($4048 per adult with MDD; Supplementary Table S8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric, educational, and work-related outcomes in offspring of parents with TRD: Swedish national registers
“Parents and their 2,359 first-born offspring, aged 6–15 years when parents were defined with TRD, were closely matched 1:1 with parent-offspring pairs with other parental depression as well as with parent-offspring pairs from the general population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjusted hazard ratios for offspring of parents with TRD were: depression 4.6 (95%CI 3.2–6.5); contact with psychiatry 3.3 (2.8–4.0); psychiatric medication 3.6 (3.0–4.2); suicide attempt 3.2 (1.9–5.5); sick leave for mental health reasons 2.3 (1.1–4.6); and disability pension 4.2 (2.2–8.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The adjusted odds ratio for non-completion of secondary school when expected was 2.1 (1.5–2.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In direct comparisons between offspring of parents with TRD vs. other depression, relative risks for all outcomes were similar, with no statistically significant differences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Not applicable.
Approaches to treatment
Current treatment options and standard of care
Antidepressant optimization, switching, and combination
CANMAT guideline: response and remission after first and second antidepressant trials
“In real-world populations, approximately half of patients with MDD achieve response (>50% reduction in symptom severity) after 8 weeks of antidepressant monotherapy, while about a third attain full symptom remission; only a quarter of nonremitters who receive a second pharmacological treatment will reach remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CANMAT guideline: dose optimization, switching, and sequencing of adjunctive strategies
“Optimizing the antidepressant dose is an important first step.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Higher than minimal therapeutic doses are more effective (to a plateau around the equivalent of 50 mg of fluoxetine) but less well-tolerated” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The evidence for the efficacy of switching antidepressants is inconsistent. Meta-analyses show that switching to another antidepressant is not superior to continuing the same one and there appears to be diminishing response rates for antidepressant monotherapy beyond the first switch.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, RCTs directly comparing switching to adjunctive strategies have shown that adjunctive strategies have superior outcomes and often similar tolerability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hence, while balancing individual risks, benefits, and patient preference, CANMAT recommends that adjunctive strategies be considered earlier in the treatment algorithm, after limited response to the first or second antidepressant trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Switching should be considered first when there is no response to the initial antidepressant or when the first medication has troublesome side effects. Adjunctive strategies should be considered first when there is a partial response to the initial antidepressant and there are minimal or no tolerability issues with the first medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CANMAT guideline: tricyclic antidepressants, MAOIs, and adjunctive antidepressants
“Hence, TCAs and MAOIs should be considered as therapeutic options when first-line and second-line medication treatments are not effective, with patients monitored carefully for side effects and potential for drug interactions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to serotonin-dopamine activity-modulating agents, antidepressants generally have a more favourable side effect profile when used as adjunctive treatment, but the evidence for efficacy is less robust.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adding mirtazapine/mianserin (antagonists of presynaptic α2-adrenoceptors) is superior to other combinations. Large RCTs have shown evidence for the effectiveness of adjunctive bupropion but the meta-analyses are inconclusive. Hence, these are recommended as second-line treatments for DTD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline: options after no or limited response to antidepressant medication
NICE guideline: combining antidepressants
VA/DoD guideline: next steps after partial or no response to initial pharmacotherapy
“Switching to psychotherapy” (opens the source at this quote in a new tab)
“Augmenting with a psychotherapy” (opens the source at this quote in a new tab)
“Augmenting with a second-generation antipsychotic” (opens the source at this quote in a new tab)
“(Weak for | Reviewed, Amended)” (opens the source at this quote in a new tab)
VA/DoD guideline: evidence on dose escalation, switching, and antidepressant combinations
ACP guideline: second-line options after nonresponse to a second-generation antidepressant
“ACP suggests one of the following options for patients in the acute phase of moderate to severe major depressive disorder who did not respond to initial treatment with an adequate dose of a second-generation antidepressant: • Switching to or augmenting with cognitive behavioral therapy (conditional recommendation; low-certainty evidence) • Switching to a different second-generation antidepressant or augmenting with a second pharmacologic treatment (see Clinical Considerations) (conditional recommendation; low-certainty evidence)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Switching after SSRI failure: remission and response with bupropion, sertraline, or venlafaxine
“We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Augmentation after SSRI failure: bupropion or buspirone added to citalopram
“We randomly assigned 565 adult outpatients who had nonpsychotic major depressive disorder without remission despite a mean of 11.9 weeks of citalopram therapy (mean final dose, 55 mg per day) to receive sustained-release bupropion (at a dose of up to 400 mg per day) as augmentation and 286 to receive buspirone (at a dose of up to 60 mg per day) as augmentation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The sustained-release bupropion group and the buspirone group had similar rates of HRSD-17 remission (29.7 percent and 30.1 percent, respectively), QIDS-SR-16 remission (39.0 percent and 32.9 percent), and QIDS-SR-16 response (31.8 percent and 26.9 percent).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“a lower dropout rate due to intolerance (12.5 percent vs. 20.6 percent, P<0.009).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Remission and relapse across four sequential treatment steps
“The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67%. Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Reanalysis of cumulative remission with the protocol-specified rating scale
“In contrast to the STAR*D-reported 67% cumulative remission rate after up to four antidepressant treatment trials, the rate was 35.0% when using the protocol-stipulated HRSD and inclusion in data analysis criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combining STAR*D’s HRSD-defined remissions with those from the non-stipulated measure increased its cumulative remission rate from 35.0% to 41.3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fourth-step treatment: MAOI versus venlafaxine plus mirtazapine
“Remission rates were not significantly different between the two treatment groups (6.9% for the tranylcypromine group and 13.7% for the venlafaxine plus mirtazapine group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tranylcypromine was associated with significantly less symptom reduction and greater attrition due to intolerance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Switching to bupropion versus bupropion or aripiprazole augmentation in veterans
“Remission rates at 12 weeks were 22.3% (n = 114) for the switch group, 26.9% (n = 136)for the augment-bupropion group, and 28.9% (n = 146) for the augment-aripiprazole group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The augment-aripiprazole group exceeded the switch group in remission (relative risk [RR], 1.30 [95% CI, 1.05-1.60]; P = .02), but other remission comparisons were not significant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anxiety was more frequent in the 2 bupropion groups (24.3% in the switch group [n = 124] vs 16.6% in the augment-aripiprazole group [n = 84]; and 22.5% in augment-bupropion group [n = 114]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Augmentation versus switching in adults aged 60 years or older
“Remission occurred in 28.9% of patients in the aripiprazole-augmentation group, 28.2% in the bupropion-augmentation group, and 19.3% in the switch-to-bupropion group. The rate of falls was highest with bupropion augmentation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In step 1, approximately 70% of the patients were adherent to aripiprazole augmentation and bupropion augmentation, but approximately 40% were adherent to the use of bupropion alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combining antidepressants versus monotherapy: meta-analysis
“Thirty-nine RCTs including 6751 patients were eligible. Combination treatment was statistically significantly associated with superior treatment outcomes relative to monotherapy (SMD = 0.31; 95% CI, 0.19-0.44). Combining a reuptake inhibitor with an antagonist of presynaptic α2-autoreceptors was superior to other combinations (SMD = 0.37; 95% CI, 0.19-0.55).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Numbers of dropouts and dropouts due to adverse events did not differ between treatments. Studies were heterogeneous, and there was indication of publication bias” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mirtazapine added to an SSRI or SNRI in treatment-resistant depression in primary care
“Beck depression inventory II scores at 12 weeks were lower in the mirtazapine group after adjustment for baseline scores and minimisation or stratification variables, although the confidence interval included the null (mean (SD) scores at 12 weeks: 18.0 (12.3) in the mirtazapine group, 19.7 (12.4) in the placebo group; adjusted difference between means −1.83 (95% confidence interval −3.92 to 0.27); P=0.09). Adverse effects were more common in the mirtazapine group and were associated with the participants stopping the trial drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Second-generation antipsychotic augmentation
CANMAT guideline: line of treatment for adjunctive atypical antipsychotics
“Adjunctive treatment with serotonin-dopamine activity modulators (also known as atypical antipsychotic agents) has the most consistent evidence for efficacy in DTD (Table 7.2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Aripiprazole and brexpiprazole are listed as first-line agents because of their efficacy and tolerability profile. Cariprazine is recommended as the second-line because there are fewer studies compared to the other agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some agents with Level 1 evidence for efficacy are recommended as second-line treatments because of the increased risk of certain side effects, including olanzapine (weight gain and metabolic side effects), quetiapine-XR (sedation and metabolic side effects), and risperidone (hyperprolactinemia, sexual side effects, and extrapyramidal symptoms).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CANMAT guideline: adverse effects and duration of adjunctive treatment
“Common side effects with aripiprazole and brexpiprazole include akathisia and weight gain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There are also potential long-term risks with these medications, such as tardive dyskinesia, although the risk is lower compared to older antipsychotics and is mitigated by the lower dosing used for MDD. In studies of conditions other than MDD, long-term use of these agents in older age may be associated with increased mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, there is little evidence available for maintenance treatment with adjunctive agents, so it is unclear how long adjunctive medications should be continued.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline: antipsychotic augmentation and monitoring
VA/DoD guideline: approved agents and adverse effects of augmentation
Aripiprazole label: indication, boxed warning, and adjunctive efficacy
Aripiprazole label: change in MADRS total score at week 6
| Study | Placebo-subtracted difference in MADRS change (95% CI) |
|---|---|
| Study 1 | “-2.84 (-4.53, -1.15)” |
| Study 2 | “-3.01 (-4.66, -1.37)” |
Aripiprazole label: adverse reactions in adjunctive trials
Brexpiprazole label: indication, boxed warning, and adjunctive efficacy
Brexpiprazole label: change in MADRS total score at week 6
| Study and dose | Placebo-subtracted difference in MADRS change (95% CI) |
|---|---|
| Study 1, 2 mg/day | “-3.2 (-4.9, -1.5)” |
| Study 2, 1 mg/day | “-1.3 (-2.7, 0.1)” |
| Study 2, 3 mg/day | “-2.0 (-3.4, -0.5)” |
Brexpiprazole label: adverse reactions in adjunctive trials
Quetiapine extended-release label: indication, boxed warning, and adjunctive efficacy
Quetiapine extended-release label: adverse reactions and metabolic warnings
Cariprazine label: indication, boxed warning, and adjunctive efficacy
Cariprazine label: adverse reactions in adjunctive trials
Olanzapine and fluoxetine label: treatment-resistant depression indication and efficacy
Olanzapine and fluoxetine label: adverse reactions and weight gain
Network meta-analysis of augmentation agents: response, remission, and discontinuation
“A total of 65 studies (N = 12,415) with 19 augmentation agents were included in the NMA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For remission rates, compared to placebo, were significant for: thyroid hormone(T4), aripiprazole, brexpiprazole, risperidone, quetiapine, and olanzapine (fluoxetine). Compared to placebo, ziprasidone, mirtazapine, and cariprazine had statistically significant higher discontinuation rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In order of efficacy, T4, aripiprazole, risperidone, quetiapine, olanzapine(fluoxetine), brexpiprazole were statistically significant compared to placebo with RRs ranging from 1.44 (1.00–2.08) for brexpiprazole to 1.91 (1.04–3.52) for T4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Meta-analysis of adjunctive atypical antipsychotics: remission, response, and harms
“All four drugs had statistically significant effects on remission, as follows: aripiprazole (odds ratio [OR], 2.01; 95% CI, 1.48–2.73), OFC (OR, 1.42; 95% CI, 1.01–2.0), quetiapine (OR, 1.79; 95% CI, 1.33–2.42), and risperidone (OR, 2.37; 95% CI, 1.31–4.30). The number needed to treat (NNT) was 19 for OFC and nine for each other drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On measures of functioning and quality of life, these medications produced either no benefit or a very small benefit, except for risperidone, which had a small-to-moderate effect on quality of life (g = 0.49).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjunctive aripiprazole was frequently associated with akathisia (NNH, 4; 95% CI, 3–6) and also linked to a statistically significant elevation in the occurrence of sedation (NNH, 14; 95% CI, 8–33) and significant weight gain of ≥7% during trials (NNH, 29; 95% CI, 10–119).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjunctive quetiapine had a very high rate of reported sedation (NNH, 3; 95% CI, 2–3)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aripiprazole augmentation in veterans: response and adverse effects
“Response was greater for the augment-aripiprazole group (74.3%) than for either the switch group (62.4%; RR, 1.19 [95% CI, 1.09-1.29]) or the augment-bupropion group (65.6%; RR, 1.13 [95% CI, 1.04-1.23]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse effects more frequent in the augment-aripiprazole group included somnolence, akathisia, and weight gain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aripiprazole augmentation in adults aged 60 years or older: well-being and falls
“The difference in the change from baseline in psychological well-being between the aripiprazole-augmentation group and the switch-to-bupropion group was 2.79 points (95% CI, 0.56 to 5.02)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In step 1, fall rates during the acute phase over a period of approximately 10 weeks were 0.33 per patient in the aripiprazole-augmentation group, 0.55 in the bupropion-augmentation group, and 0.38 in the switch-to-bupropion group (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lithium and thyroid hormone augmentation
CANMAT guideline: lithium and triiodothyronine as second-line adjuncts
“Both medications were included in a network meta-analysis evaluating all adjunctive options. While both lithium and triiodothyronine had evidence for efficacy, the included RCTs predated 2003, had small sample sizes and involved adjunctive use with TCAs only. Lithium also requires serum level monitoring and triiodothyronine requires monitoring of thyroid levels. Hence, lithium and triiodothyronine continue to be second-line recommendations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline: lithium and liothyronine augmentation and lithium monitoring
VA/DoD guideline: lithium and liothyronine with insufficient evidence for or against
VA/DoD guideline: liothyronine remission and cautions
Third-step augmentation: lithium versus triiodothyronine
“A total of 142 adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or who were intolerant to an initial prospective treatment with citalopram and a second switch or augmentation trial were randomly assigned to augmentation with lithium (up to 900 mg/day; N=69) or with T(3) (up to 50 mug/day; N=73) for up to 14 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After a mean of 9.6 weeks (SD=5.2) of treatment, remission rates were 15.9% with lithium augmentation and 24.7% with T(3) augmentation, although the difference between treatments was not statistically significant. Lithium was more frequently associated with side effects (p=0.045), and more participants in the lithium group left treatment because of side effects (23.2% versus 9.6%; p=0.027).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lithium augmentation versus placebo: meta-analysis
“Nine trials that included 237 patients were selected. The odds ratio for response to lithium vs. placebo in all contrasts combined was 2.89 (95% CI 1.65, 5.05, z=3.72, p=0.0002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjunctive lithium was effective with TCAs (7 contrasts) and with second generation agents (3 contrasts). Discontinuation due to adverse events was infrequent and did not differ between lithium and placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The meta-analysis is limited by the small size and number of trials and limited data for treatment resistant patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis of augmentation agents: lithium and thyroid hormones
“In order of decreasing efficacy, T3, nortriptyline, aripiprazole, brexpiprazole, quetiapine, lithium, modafinil, olanzapine (fluoxetine), cariprazine and lisdexamfetamine were statistically significant compared to placebo, with RRs ranging from 1.18 (1.03–1.37) for lisdexamfetamine to 1.90 (1.16–3.11) for T3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, we should acknowledge that remission rates were not significant compared to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, in a post-hoc sub-analysis of only three short-term studies (≤3 weeks) we found that response rates were not significant as compared to placebo (RR= 1.79; 0.48–6.67).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Thyroid hormone augmentation in unipolar treatment-resistant depression: meta-analysis
“Based on the screening of these records, we identified 10 studies that met the inclusion criteria (total number of patients = 663). The comparison of response to thyroid hormones vs. placebo resulted in an odds ratio of 1.56 (95% CI: 0.50-4.84). Similarly, the comparison of response to thyroid hormones vs. lithium resulted in an odds ratio of 1.91 (95% CI: 0.85-4.26).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“According to this review and meta-analysis, there is not sufficient evidence to support the use of adjunctive thyroid hormones for treatment-resistant unipolar depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lithium versus quetiapine augmentation over 12 months
“Participants in the quetiapine group had a significantly lower overall burden of depressive symptom severity than participants in the lithium group (area under the between-group differences curve -68·36 [95% CI -129·95 to -6·76; p=0·0296). Time to discontinuation did not significantly differ between the two groups. Quetiapine was more cost-effective than lithium.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Results of the trial suggest that quetiapine is more clinically effective than lithium as a first-line augmentation option for reducing symptoms of depression in the long-term management of treatment-resistant depression, and is probably more cost-effective than lithium.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lithium augmentation versus switch to nortriptyline in adults aged 60 years or older
“Remission occurred in 18.9% of patients in the lithium-augmentation group and 21.5% in the switch-to-nortriptyline group; rates of falling were similar in the two groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our trial, less than 10% of the patients who switched to bupropion or had augmentation with lithium both reached and maintained the target dose and had remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lithium label: boxed warning on toxicity and renal effects
Psychotherapy
CANMAT guideline: psychotherapy after poor response to an initial antidepressant
“Based on efficacy and low potential for side effects, first-line psychological treatments should be considered early in the treatment course” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There are few studies of psychotherapy for patients showing poor response to antidepressants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hence, CBT is recommended as a second-line adjunctive treatment, with medications, for DTD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline: psychological therapy after no or limited response to medication
VA/DoD guideline: switching to or augmenting with psychotherapy
VA/DoD guideline: patient burden and access to psychotherapy
ACP guideline: switching to or augmenting with cognitive behavioral therapy
“ACP suggests one of the following options for patients in the acute phase of moderate to severe major depressive disorder who did not respond to initial treatment with an adequate dose of a second-generation antidepressant: • Switching to or augmenting with cognitive behavioral therapy (conditional recommendation; low-certainty evidence)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cognitive behavioral therapy added to usual care in primary care: response at 6 months
“This two parallel-group multicentre randomised controlled trial recruited 469 patients aged 18-75 years with treatment resistant depression (on antidepressants for ≥6 weeks, Beck depression inventory [BDI] score ≥14 and international classification of diseases [ICD]-10 criteria for depression) from 73 UK general practices.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary outcome was response, defined as at least 50% reduction in depressive symptoms (BDI score) at 6 months compared with baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“95 participants (46%) in the intervention group met criteria for response at 6 months compared with 46 (22%) in the usual care group (odds ratio 3·26, 95% CI 2·10-5·06, p<0·001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because of the nature of the intervention it was not possible to mask participants, general practitioners, CBT therapists, or researchers to the treatment allocation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cognitive behavioral therapy added to usual care: long-term follow-up and cost-effectiveness
“Of these, 248 individuals completed a long-term follow-up questionnaire and provided data for the primary outcome (136 in the intervention group vs 112 in the usual care group). At follow-up (median 45·5 months [IQR 42·5-51·1]), the intervention group had a mean BDI-II score of 19·2 (SD 13·8) compared with a mean BDI-II score of 23·4 (SD 13·2) for the usual care group (repeated measures analysis over the 46 months: difference in means -4·7 [95% CI -6·4 to -3·0, p<0·001]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average annual cost of trial CBT per participant was £343 (SD 129). The incremental cost-effectiveness ratio was £5374 per QALY gain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychological therapies for treatment-resistant depression: Cochrane review
“We included six trials (n = 698; most participants were women approximately 40 years of age). All studies evaluated psychotherapy plus usual care (with antidepressants) versus usual care (with antidepressants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moderate‐quality evidence for remission from six studies (RR 1.92, 95% CI 1.46 to 2.52; n = 635) and low‐quality evidence for response from four studies (RR 1.80, 95% CI 1.2 to 2.7; n = 556) indicate that psychotherapy was beneficial as an adjunct to usual care over the short term.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High‐quality evidence shows no differential dropout (a measure of acceptability) between intervention and comparator groups over the short term (RR 0.85, 95% CI 0.58 to 1.24; six studies; n = 698).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No evidence currently shows whether switching to a psychotherapy is more beneficial for this patient group than continuing an antidepressant medication regimen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychotherapy for treatment-resistant depression: meta-analysis and meta-regression
“Seven different psychotherapies were studied in 21 trials that included a total of 25 comparisons. In three comparisons of psychotherapy v. treatment as usual (TAU) we found no evidence to conclude that there is a significant benefit of psychotherapy as compared with TAU. In 22 comparisons of add-on psychotherapy plus TAU v. TAU only, we found a moderate general effect size of 0.42 (95% CI 0.29-0.54) in favor of psychotherapy plus TAU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most frequent investigated treatments were cognitive behavior therapy, interpersonal psychotherapy, mindfulness-based cognitive therapy, and cognitive behavioral analysis system of psychotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Esketamine and ketamine
CANMAT guideline: second-line adjunctive ketamine and intranasal esketamine
“which is approved by several regulatory agencies as an add-on treatment to an SSRI/SNRI or other antidepressant, for patients failing at least 2 adequate antidepressant trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is also growing evidence for relapse-prevention efficacy for both medications, with maintenance doses administered every 1 to 4 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, side effect potential and feasibility issues (i.e., the required monitoring of blood pressure and dissociative side effects) have downgraded adjunctive ketamine and intranasal esketamine to second-line recommendation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VA/DoD guideline: ketamine or esketamine after several pharmacologic trials
NICE guideline: esketamine nasal spray not recommended
ICER assessment: esketamine and intravenous ketamine as comparators for psilocybin
Esketamine FDA-approved indications, including monotherapy
Esketamine dosing in treatment-resistant depression
Esketamine REMS and post-dose monitoring
Esketamine adverse reactions, contraindications, and blood pressure monitoring
Esketamine monotherapy study: change in MADRS total score at Day 28
TRANSFORM-2: esketamine plus a new oral antidepressant at Day 28
“The study enrolled adults with moderate to severe nonpsychotic depression and a history of nonresponse to at least two antidepressants in the current episode, with one antidepressant assessed prospectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 435 patients screened, 227 underwent randomization and 197 completed the 28-day double-blind treatment phase.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Change in MADRS score with esketamine plus antidepressant was significantly greater than with antidepressant plus placebo at day 28 (difference of least square means=-4.0, SE=1.69, 95% CI=-7.31, -0.64)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“7% and 0.9% of patients in the respective treatment groups discontinued study drug because of an adverse event.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
TRANSFORM-3: esketamine in adults aged 65 years and older
“For the primary endpoint, the median-unbiased estimate of the treatment difference (95% CI) was -3.6 (-7.20, 0.07); weighted combination test using MMRM analyses z = 1.89, two-sided p = 0.059.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Esketamine/antidepressant did not achieve statistical significance for the primary endpoint.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SUSTAIN-1: relapse prevention with continued esketamine
“Among the 297 adults (mean age [SD], 46.3 [11.13] years; 197 [66.3%] female) who entered the randomized maintenance phase, 176 achieved stable remission; 24 (26.7%) in the esketamine and antidepressant group and 39 (45.3%) in the antidepressant and placebo group experienced relapse (log-rank P = .003, number needed to treat [NNT], 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Esketamine and antidepressant treatment decreased the risk of relapse by 51% (hazard ratio [HR], 0.49; 95% CI, 0.29-0.84) among patients who achieved stable remission and 70% (HR, 0.30; 95% CI, 0.16-0.55) among those who achieved stable response compared with antidepressant and placebo treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SUSTAIN-3: long-term safety and maintenance of response
“At the interim data cutoff (01 December 2020), 1148 participants were enrolled, 458 at induction and 690 at optimization/maintenance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Common treatment-emergent adverse events (≥20%) were headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with 35.6% and 46.1% of participants in remission (MADRS total score ≤12) at induction and optimization/maintenance endpoints, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serious adverse events were reported for 171 (14.9%) of the 1148 participants during SUSTAIN-3, over 2769 cumulative patient-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESCAPE-TRD: esketamine compared with extended-release quetiapine augmentation
“Overall, 336 patients were assigned to the esketamine group and 340 to the quetiapine group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More patients in the esketamine group than in the quetiapine group had remission at week 8 (91 of 336 patients [27.1%] vs. 60 of 340 patients [17.6%]; P = 0.003) and had no relapse through week 32 after remission at week 8 (73 of 336 patients [21.7%] vs. 48 of 340 patients [14.1%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In an open-label, single-blind (with raters unaware of group assignments), multicenter, phase 3b, randomized, active-controlled trial” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ELEKT-D: intravenous ketamine compared with electroconvulsive therapy
“During an initial 3-week treatment phase, patients received either ECT three times per week or ketamine (0.5 mg per kilogram of body weight over 40 minutes) twice per week.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 403 patients underwent randomization at five clinical sites; 200 patients were assigned to the ketamine group and 203 to the ECT group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response (difference, 14.2 percentage points; 95% confidence interval, 3.9 to 24.2; P<0.001 for the noninferiority of ketamine to ECT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ECT was associated with musculoskeletal adverse effects, whereas ketamine was associated with dissociation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ketamine and esketamine: Cochrane meta-analysis
“The evidence suggests that ketamine may result in an increase in response and remission compared with placebo at 24 hours odds ratio (OR) 3.94, 95% confidence interval (CI) 1.54 to 10.10; n = 185, studies = 7, very low-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Esketamine treatment likely results in a large increase in participants achieving remission at 24 hours compared with placebo (OR 2.74, 95% CI 1.71 to 4.40; n = 894, studies = 5, moderate-certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The effects of ketamine lasted no more than one week after treatment and clearly disappeared after two weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Esketamine caused a lot more side effects than placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Repetitive transcranial magnetic stimulation
CANMAT guideline: rTMS and theta burst protocols
“Repetitive TMS shows efficacy for DTD, with response rates of 40% to 50%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High-frequency (5 Hz or higher) rTMS delivered over the left dorsolateral prefrontal cortex (DLPFC) has the largest evidence base and is recommended as a first-line protocol, along with low-frequency (1 Hz or lower) rTMS delivered over the right DLPFC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TBS is recommended as a first-line protocol” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Accelerated iTBS to the left DLPFC has evidence for efficacy and a large RCT found no significant differences between accelerated bilateral TBS and high frequency rTMS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unlike ECT, rTMS does not require anaesthesia and has no cognitive side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, except in emergent situations as mentioned above, rTMS should generally be considered before ECT, given its less invasive nature and that individuals may continue to work or attend school while undergoing rTMS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VA/DoD guideline: rTMS after two or more pharmacologic trials
NICE interventional procedures guidance on rTMS
Pivotal sham-controlled trial of left prefrontal TMS
“In a double-blind, multisite study, 301 medication-free patients with major depression who had not benefited from prior treatment were randomized to active (n = 155) or sham TMS (n = 146) conditions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Remission rates were approximately twofold higher with active TMS at week 6 and significant on the MADRS and HAMD24 scales (but not the HAMD17 scale).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Active TMS was well tolerated with a low dropout rate for adverse events (4.5%) that were generally mild and limited to transient scalp discomfort or pain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
OPT-TMS: sham-controlled trial in antidepressant-free outpatients
“Primary efficacy analysis revealed a significant effect of treatment on the proportion of remitters (14.1% active rTMS and 5.1% sham) (P = .02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The number needed to treat was 12. Most remitters had low antidepressant treatment resistance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
THREE-D: intermittent theta burst compared with 10 Hz rTMS
“Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered in 3 min, versus 37·5 min for a standard 10 Hz treatment session.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between Sept 3, 2013, and Oct 3, 2016, we randomly allocated 205 participants to receive 10 Hz rTMS and 209 participants to receive iTBS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with treatment-resistant depression, iTBS was non-inferior to 10 Hz rTMS for the treatment of depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common treatment-related adverse event was headache in both groups (10 Hz rTMS: 131 [64%] of 204; iTBS: 136 [65%] of 208).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis of non-surgical brain stimulation
“113 trials (262 treatment arms) that randomised 6750 patients (mean age 47.9 years; 59% women) with major depressive disorder or bipolar depression met the inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“low frequency right rTMS (3.65, 2.13 to 6.24), intermittent theta burst stimulation (3.20, 1.45 to 7.08), high frequency left rTMS (3.17, 2.29 to 4.37)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All treatment strategies were at least as acceptable as sham therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Stanford neuromodulation therapy: FDA clearance
Stanford neuromodulation therapy: initial sham-controlled trial
“The authors addressed these limitations by developing a neuroscience-informed accelerated iTBS protocol, Stanford neuromodulation therapy (SNT; previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the planned interim analysis, 32 participants with treatment-resistant depression had been enrolled, and 29 participants who continued to meet inclusion criteria received either active (N=14) or sham (N=15) SNT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean percent reduction from baseline in MADRS score 4 weeks after treatment was 52.5% in the active treatment group and 11.1% in the sham treatment group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Stanford neuromodulation therapy: confirmatory sham-controlled trial
“In the current RCT, 53 participants with TRD were enrolled, and 48 who continued to meet entry criteria were randomized to receive active (N=24) or sham (N=24) SNT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 1-month, remission (primary outcome) was achieved in 50.0% of active vs. 20.8% of sham participants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Electroconvulsive therapy
CANMAT guideline: efficacy, course, and cognitive effects of ECT
“ECT remains one of the most effective treatment options for patients with TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ECT has demonstrated evidence of efficacy and tolerability in the treatment of depressive episodes, with response rates ranging from 65% to 75%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An acute course of ECT usually requires 6 to 12 sessions, with no difference in response outcomes between sessions given twice or thrice weekly” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse effects on cognition are of most concern, although modern ECT techniques, including unilateral electrode placement and refined electrical dosing, have reduced both the incidence and severity of cognitive side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, some patients report significant and distressing gaps in autobiographical memory long after ECT, and the discrepancy between cognitive performance and subjective memory dysfunction remains controversial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although ECT has high response rates during acute treatment, recurrence occurs in 60% to 80% of patients at 6-month follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VA/DoD guideline: ECT for severe depression
NICE guideline: ECT for severe depression
Meta-analysis of ECT compared with simulated ECT and pharmacotherapy
“Real ECT was significantly more effective than simulated ECT (six trials, 256 patients, standardised effect size [SES] -0.91, 95% CI -1.27 to -0.54).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment with ECT was significantly more effective than pharmacotherapy (18 trials, 1144 participants, SES -0.80, 95% CI -1.29 to -0.29).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ECT remission after antidepressant pharmacotherapy failure
Network meta-analysis: response with ECT compared with sham
ELEKT-D: ECT compared with intravenous ketamine, including memory outcomes
“A total of 55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response (difference, 14.2 percentage points; 95% confidence interval, 3.9 to 24.2; P<0.001 for the noninferiority of ketamine to ECT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ECT appeared to be associated with a decrease in memory recall after 3 weeks of treatment (mean [±SE] decrease in the T-score for delayed recall on the Hopkins Verbal Learning Test-Revised, -0.9±1.1 in the ketamine group vs. -9.7±1.2 in the ECT group; scores range from -300 to 200, with higher scores indicating better function) with gradual recovery during follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Objective cognitive performance after ECT
“Twenty-four cognitive variables (84 studies, 2981 patients) were meta-analyzed. No standardized retrograde amnesia tests were identified.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Significant decreases in cognitive performance were observed 0 to 3 days after ECT in 72% of variables” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cognitive abnormalities associated with ECT are mainly limited to the first 3 days posttreatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Relapse after successful ECT
“In modern era studies of continuation pharmacotherapy, 51.1% (95% CI=44.7–57.4%) of patients relapsed by 12 months following successful initial treatment with ECT, with the majority (37.7%, 95% CI=30.7–45.2%) relapsing within the first 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vagus nerve stimulation and other neuromodulation
CANMAT guideline: VNS third-line, DBS investigational
“To date, there are very few RCTs involving VNS, and these studies have failed to demonstrate the efficacy of VNS compared to sham control conditions in the short term.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“VNS is generally safe and well tolerated, with the most common side effects involving pain related to device implantation, voice hoarseness or alteration (due to intermittent stimulation of the larynx), coughing, headache, sore throat, and neck pain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, VNS is the only surgical neuromodulation treatment approved for TRD by regulatory agencies and is recommended as a third-line option” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DBS and MST are currently considered investigational due to limited available evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VA/DoD guideline: against VNS and DBS outside research
NICE interventional procedures guidance on implanted VNS
Medicare coverage of VNS limited to coverage with evidence development
RECOVER: 12-month sham-controlled trial
“This 12-month, multicenter, double-blind, sham-controlled trial included 493 adults with marked treatment-resistant major depression who were randomized to active or no-stimulation sham VNS for 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Percent time in MADRS response did not distinguish active from sham VNS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Active VNS exceeded sham VNS in rate of dyspnea (P = 0.035), a known side effect of VNS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
RECOVER: quality of life and function
“Active VNS was superior to sham in mean change in scores from baseline in the Mini-Q-LES-Q (P = 0.050) and WPAI item 6 (health condition's effect on regular activities [P = 0.050]) used as continuous variables, with a similar trend for Q-LES-Q (P = 0.061).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
RECOVER: durability of benefit over 24 months
“Prospective, open-label, single-arm, long-term extension study (RECOVER) conducted from September 2019 to April 2025.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Depressive symptom, daily function, and QoL benefits obtained after 12 months of adjunctive VNS were sustained in about 80% of participants continuing VNS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It did not demonstrate that VNS was necessary in achieving this sustained benefit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conducting the study was also supported by the Centers for Medicare & Medicaid Services.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Five-year registry: adjunctive VNS compared with treatment as usual
“This 5-year, prospective, open-label, nonrandomized, observational registry study was conducted at 61 U.S. sites and included 795 patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Deep brain stimulation of the ventral anterior limb of the internal capsule
“Following the optimization phase, which lasted 51.6 (22.0) weeks, 10 patients (40%) were classified as responders and 15 individuals (60%) as nonresponders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During active DBS, patients scored significantly lower on the HAM-D-17 scale (13.6 [95% CI, 9.8-17.4]) than during sham DBS (23.1 [95% CI, 20.6-25.6]) (P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Serious adverse events included severe nausea during surgery (1 patient), suicide attempt (4 patients), and suicidal ideation (2 patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
In the Sequenced Treatment Alternatives to Relieve Depression trial, remission rates fell from 36.8% at step 1 to 13.0% at step 4, with higher relapse rates after more steps, and a reanalysis with the protocol-stipulated HRSD found a cumulative remission rate of 35.0% against the reported 67%. ICER's draft scope states that another antidepressant course succeeds much less often in TRD. Adjunctive atypical antipsychotics have a “greater side effect burden than antidepressant monotherapy”: one analysis reported akathisia with aripiprazole (NNH 4) and sedation with quetiapine (NNH 3), and one study found higher all-cause mortality with antipsychotic use (HR 1.21). Esketamine is dispensed and administered only in certified healthcare settings, with monitoring for at least 2 hours at each session, and ketamine and esketamine often require repeated visits for maintenance doses and have limited access in some regions. In one analysis, ketamine effects lasted no more than one week. After successful ECT, 51.1% of patients relapsed by 12 months on continuation pharmacotherapy, and ECT use is limited by stigma, general anaesthesia, and concern about cognitive effects. rTMS requires daily clinic visits, psychotherapy can be burdensome because of frequent visits, and access is limited because not all providers have adequate training, and VNS carries a greater than 5% chance of significant adverse events.
Diminishing remission with each successive treatment step
“The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Reanalysis of cumulative remission in the Sequenced Treatment Alternatives to Relieve Depression trial
“In contrast to the STAR*D-reported 67% cumulative remission rate after up to four antidepressant treatment trials, the rate was 35.0% when using the protocol-stipulated HRSD and inclusion in data analysis criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tolerability of adjunctive antipsychotics
“Adjunctive strategies, especially with atypical antipsychotic agents (serotonin and dopamine activity modulators), have greater evidence for efficacy and shorter time to response or remission, but they generally have a greater side effect burden than antidepressant monotherapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, antipsychotic users had increased risk of all-cause mortality (hazard ratio 1.21; 95% CI 1.07-1.33).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These findings do not support the use of antipsychotic augmentation in patients with treatment-resistant depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Esketamine: certified settings and two-hour observation at each session
Ketamine and esketamine: treatment space, repeated visits, and regional access
ECT: stigma, anaesthesia, cognitive effects, and relapse
“However, the clinical use of ECT is often hindered by stigma, the need for general anaesthesia, concern about cognitive adverse effects, and high rates of relapse after acute treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neuromodulation: availability, daily visits, and specialized personnel
“because of feasibility issues, including limited availability (especially in the public health sector), patient burden (e.g., requiring daily clinic visits for rTMS), and the need for specialized personnel (e.g., anaesthesiologists for ECT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VNS: surgical implantation and adverse events
Place in treatment, anticipated use, and care setting
Summary
COMPASS has submitted a New Drug Application for COMP360 for TRD, which its press release defines as an inadequate response to two or more courses of antidepressants of adequate dose and duration. Guidelines that address psilocybin restrict it to research: the VA/DoD guideline recommends against psilocybin for MDD “outside of a research setting”, with very low confidence in the evidence; the CANMAT guideline update considers psilocybin-assisted psychotherapies “investigational treatments”; and a CANMAT task force recommends use primarily within clinical trials. The EMA guideline recommends starting psychedelic development in TRD and states that psychedelics need administration “in a controlled environment”. ICER's draft scope assesses psilocybin 25 mg in adults with MDD without psychotic features after two or more failed adequate antidepressant trials in the current episode, with esketamine, intravenous ketamine, and rTMS as comparators focusing on US outpatient settings. The company's November 2026 investor presentation states that dosing and monitoring will take place at a certified treatment center, and its quarterly release cites more than 8,500 treatment centers. The company described one or two initial administrations followed by episodic dosing per physician decision. Payer panel participants named head-to-head trials against esketamine or other active comparators as the most important evidence for coverage.
VA/DoD guideline: recommendation against psilocybin outside a research setting
CANMAT 2023 update: psilocybin-assisted psychotherapy considered investigational
“Psychedelic-assisted psychotherapy was recently reviewed in a CANMAT Task Force Report.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although these results are promising, they are limited by ongoing methodological issues (e.g., lack of blinding, inadequate assessment of expectancy bias, heterogeneity of psychological support, and lack of long-term safety data).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hence, psilocybin- and other psychedelic-assisted psychotherapies are considered investigational treatments” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CANMAT task force: psilocybin an experimental treatment for use within clinical trials
“There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As such, Canadian Network for Mood and Anxiety Treatments considers psilocybin an experimental treatment and recommends its use primarily within clinical trials, or, less commonly, through the special access program in rare, special circumstances.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EMA depression guideline: psychedelic development in treatment-resistant depression and a controlled environment
NICE guideline recommendations for treatment-resistant depression
ICER assessment scope: population, intervention, comparators, and setting
Company statements on intended position in treatment-resistant depression
Anticipated dosing pattern: one or two initial administrations, then episodic retreatment
Anticipated care setting: certified interventional psychiatry treatment centers
Payer panel perspectives on the place of psilocybin in therapy
“Perspectives among participants on the current evidence for psilocybin in TRD were mixed, with some indicating it is compelling or promising and their organization would likely cover upon FDA approval and others indicating it is uncertain or insufficient and would likely adopt a wait-and-see approach to coverage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These participants cited the lack of clinical treatment guidelines, comparative studies, and cost-effectiveness data as particular challenges when trying to determine the place in therapy of a new treatment and make coverage decisions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants indicated that the most important evidence required to support coverage of psilocybin would be head-to-head trials vs esketamine or other active comparators such as SGAs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
Intensity of the psychedelic experience and Week 3 response in the phase 2b trial
“The mean intensity of psychedelic effects was dose-related, but distributions of scores for different doses overlapped considerably.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the 25 mg dose, 5D-ASC dimensions Oceanic Boundlessness (Pearson correlation coefficient r = -0.508) and Visual Restructuralization (r = -0.516), and EBI (r = -0·637) were the variables with the strongest correlation to the Week 3 change from Baseline in MADRS score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The existence of correlation does not establish causation and exploratory findings require further replication, preferably in larger independent samples.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Therapeutic alliance and Week 3 response in the phase 2b trial
“Change from Baseline to Week 3 MADRS scores showed weaker correlations with pre-dosing therapeutic alliance (-0.178) than with measures of the psychedelic experience: EBI (-0.637), Oceanic Boundlessness (-0.508), and Visual Restructuralization (-0.516).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The effects of the alliance itself on therapeutic efficacy were either limited or absent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pretreatment clinical characteristics and the psychedelic experience
“Dose was the strongest and most consistent predictor of the psychedelic experience.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Positive affect, lower generalized anxiety symptoms, higher executive functioning, and greater personality disorder symptoms had significant effects on different aspects of the subjective psychedelic experience.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Antidepressant discontinuation before dosing
“Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No significant differences were found between medication discontinued (n = 18) and unmedicated at screening (UAS) (n = 9) groups in clinician rated depression (p = 0.759), self-reported depression (p = 0.215), anxiety (p = 0.178), and suicidality (p = 0.882) symptoms over time, with both groups having clinically significant benefits on all outcomes assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant SSRI treatment in an open-label adjunctive study
“in fact, the response and remission rates were higher in the current study (42% response and remission rates at Week 3 verses 37% and 29%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Future research should examine whether the outcomes of psilocybin as a monotherapy or as an adjunct to SSRIs remain comparable in a longer term follow up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severe treatment resistance and comorbid PTSD in an open-label single-site study
“Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Depressive symptoms were significantly decreased at week 3 (MADRS least-squares mean change=-15.8, 95% CI=-25.4 to -6.3) and Week 12 (MADRS least-squares mean change=-17.2, 95% CI=-25.2 to -9.1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In exploratory analyses, the Oceanic Boundlessness (OB) dimension of the psychedelic experience correlated with post-dosing antidepressant responses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with comorbid PTSD (N=5) showed significantly less antidepressant effect of psilocybin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Veterans with severe treatment resistance in the same open-label study
“Of 15 participants, 60 % met response and 53 % met remission criteria at Week 3.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Co-morbid PTSD did not significantly influence study outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The psychedelic experience reported in 5D-ASC did not correlate with response.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Number of prior treatment failures: company statements
Early prediction of response from language in the post-dosing session
“While the phase-IIb results are promising, the treatment works for a portion of the population and early prediction of outcome is a key objective as it would allow early identification of those likely to require alternative treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two multinomial logistic regression models were fit to predict responder status at week 3 and through week 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cross-validation of these models resulted in 85% and 88% accuracy and AUC values of 88% and 85%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Control-group response in psilocybin trials compared with SSRI and esketamine trials
“MADRS response rates for control treatments in SSRI trials were 14 percentage points higher than in psilocybin trials and in esketamine trials were 23 percentage points higher than in psilocybin trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The poor control treatment outcomes in psilocybin trials suggest that it may not be as broadly effective for depression as estimated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the effect size (standardised mean difference) of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm changed from placebo response in the psychedelic trials to antidepressant trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial methodology and study size as moderators in meta-analyses
“The subgroup analyses found larger effects, albeit non-significant differences in subgroup heterogeneity, associated with studies that administered psilocybin in bodyweight-adjusted doses and provided longer preparation, dosing, and integration sessions and provided non-manualized psychotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose-response by type of depression
Regulatory expectations for characterizing variability in response
Payer requests for subgroup data
“Other data participants saw as important included subgroup analyses to elucidate the appropriate treatment population and potential budget impact, and data to assess cost-effectiveness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“They also highlighted that treatment effect is likely more variable given the nature of the treatment and additional, longer-term data will be necessary to increase the predictability of response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
FDA direction to use the Spravato REMS as a template
Spravato REMS requirements named as the template
Session monitoring: FDA guidance and company plans
FDA guidance on postmarketing risk mitigation and the psychotherapy component
Three-phase psychological support model used in COMP360 trials
“The authors also outline the therapist training, mentoring, and fidelity assessment programs they have developed to ensure the quality and consistency of the CPSM delivery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Training consists of four components: an online learning platform; in-person training; applied clinical training; and ongoing individual mentoring and participation in webinars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As part of the phase IIb study of psilocybin therapy for treatment-resistant depression, 65 health care professionals have been fully trained as therapists and assisting therapists, across the US, Canada and Europe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-directive support during the administration session
“Speech by either party during the administration sessions was rare; on average, 78% of the time was filled with silence, compared to 25% to 30% in non-administration sessions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Company site-readiness and patient support programs
Payer coverage criteria and reauthorization proposed for psilocybin
“All payer participants agreed that coverage criteria would align with the FDA-approved product label including, for instance, the quantity and frequency of treatment, and would comply with the REMS requirements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several added they would look to previous experience with esketamine for guidance and that coverage criteria for psilocybin may be similar.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Whereas some participants would accept provider attestation for continuation of therapy, others would require documentation of improvement and sustained treatment response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One PBM participant suggested that reviewing claims for other TRD treatments subsequent to psilocybin administration could further support determination of treatment response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants discussed reimbursement considerations with coverage of psilocybin including developing a bundled payment model combining all related services (eg, medication, administration, psychotherapy) into a single billable episode of care” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network adequacy and workforce
“Participants identified the shortage of qualified mental health professionals, both in general and as part of their organizations’ networks, as a primary challenge with equitable access to psilocybin treatment and post-treatment care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants expressed concern related to the potential requirements for equitable access to specialized administration sites because the number of these may be limited, especially in rural areas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
State-licensed psilocybin services in Oregon as a delivery analog
“Results indicated that in the 16 active training programs, the mean tuition was $9,359 and half offered diversity scholarships.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean planned price for a session was $1,388 and the most common areas of specialization were trauma, mental disorders, consciousness exploration, and spirituality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychological support delivery in a publicly funded health service
“Oral psychedelics such as psilocybin have an acute effect evolving over 6-8 h and are generally given in combination with psychological support.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this feature, we discuss these issues and outline a model for psychological support delivery in publicly funded health services such as the National Health Service.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Measurement-based care in major depression
Executive Order 14401: Right to Try access and federal-state programs
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Pooled effect of psilocybin-assisted therapy in meta-analyses of randomized trials
“The pooled SMD for 1-week between-group change in depression ratings was -0.72 [95% CI, -0.95 to -0.49; I2 = 17%; 5 RCTs; n = 403], favouring PAT; results were similar at days 2, 14, and 42.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The response [RR = 3.42; 95% CI, 2.35-4.97; I2 = 0%; 4 RCTs; n = 373] and remission [RR = 3.66; 95% CI, 2.26-5.92; I2 = 0%; 4 RCTs; n = 373] rates also favored PAT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Within-group change in psilocybin, SSRI, and esketamine trials
“Pretreatment to posttreatment SMCs (SEMs) were 1.21 (0.15) for psilocybin, 1.28 (0.06) for SSRIs, and 1.43 (0.15) for esketamine and were 0.50 (0.15), 1.00 (0.08), and 1.12 (0.17) for their respective control treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relative effect compared with escitalopram in a network meta-analysis
Phase 2b trial: response, remission, and sustained response after a single 25 mg dose
“In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Durability after a single dose over 52 weeks
“For all COMP 001 patients (n = 233), median time to depressive event was greater for the 25 mg group (92 days) compared to the 10 mg (83 days) and 1 mg (62 days) groups, with the majority of participants having had a depressive event by Week 12 (25 mg n = 37/75, 10 mg n = 38/79, 1 mg n = 44/75).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Company-reported response, remission, and durability with retreatment
Independent phase 2b trial in treatment-resistant depression with an active placebo
“Response rates on the primary end point were 17.0% in the group receiving psilocybin, 25 mg; 12.5% in the group receiving psilocybin, 5 mg; and 10.6% in the group receiving nicotinamide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this randomized clinical trial, psilocybin, 25 mg, with adjunct psychotherapy, was associated with a clinically meaningful reduction in depressive symptoms in individuals with TRD, although findings did not show a significant effect on the primary outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world outcomes outside controlled trials
“Response and remission rates were 33.3% and 22.2% (MADRS), and 27.8% and 27.8% (BDI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocybin was associated with a clinically meaningful reduction in depressive symptoms, with response and remission rates below those reported in previous trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term outcomes in veterans with severe treatment resistance
“At Month 12, 40 % maintained response and 30 % maintained remission.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the antidepressant effects began to wane at 6 months, and then more substantially after 9 months, although these increases in MADRS did not reach statistical significance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory statement on the evidence for durability and retreatment
Expected outcomes with further conventional treatment steps or usual care
“The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 12- and 24-month IDS-SR-30 response rates were 11.6% (13/112) and 18.4% (19/103), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 12- and 24-month IDS-SR-30 remission rates were 3.6% (4/112) and 7.8% (8/103), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the short term, TRD was highly recurrent with as many as 80% of those requiring multiple treatments relapsing within a year of achieving remission.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote